Gefitinib (ZD1839)

目录号：S1025

Molecular Weight(MW): 446.90

Gefitinib (ZD1839)是一种EGFR抑制剂，作用于NR6wtEGFR和NR6W细胞中的Tyr1173，Tyr992，Tyr1173和Tyr992，IC50 分别为37 nM，37nM，26 nM和57 nM。

规格

价格

库存

购买数量

10mM (in 1mL DMSO)	RMB 1574.78	现货
100mg	RMB 1227.69	现货
250mg	RMB 2205.98	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户购买Selleck的此次产品后发表的文献93篇：

Nature, 2017, 547(7664):453-457

PubMed: 28678785

Nature, 2014, 508(7494):118-22

PubMed: 24670642

Nature, 2012, 483(7387):100-3

PubMed: 22281684

Cell, 2012, 151(5):937-50

PubMed: 23178117

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847

Mol Cell, 2014, 55(6):904-15

PubMed: 25219500

Ann Oncol, 2013, 24(2):362-9

PubMed: 22967992

Nat Commun, 2015, 6:6377

PubMed: 25758528

J Thorac Oncol, 2015, 10.1097/JTO.0000000000000500

PubMed: 25658629
Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158

Mol Syst Biol, 2011, 7:486

PubMed: 21525872

Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934

Cell Death Differ, 2012, 19(12):1908-16

PubMed: 22722337

Int J Cancer, 2014, 134(11):2560-71

PubMed: 24374738

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806

Oncogene, 2014, 33(19):2495-503

PubMed: 23728339

Oncogene, 2014, 33(35):4385-95

PubMed: 24096476
Oncogene, 2012, 32(34):4034-42

PubMed: 22964644

Oncogene, 2011, 30(6):737-50

PubMed: 20890302

MBio, 2014, 5(4):e01340-14

PubMed: 25096879

Cancer Lett, 2014, 342(1):82-91

PubMed: 24001610

Cancer Lett, 2012, 321(2):187-94

PubMed: 22343320

J Pathol, 2016, 239(3):320-34

PubMed: 27102572

J Clin Endocrinol Metab, 2013, 98(6):2502-12

PubMed: 23559083

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768

Mol Cancer Ther, 2013, 13(2):444-53

PubMed: 24258346

Mol Cancer Ther, 2013, 12(11):2541-58

PubMed: 24026012

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348
Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087

Carcinogenesis, 2013, 34(9):1994-9

PubMed: 23677069

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598

Radiother Oncol, 2013, 108(3):473-8

PubMed: 23891090

Cell Oncol , 2014, 37(5):377-86

PubMed: 25228008

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556

Antivir Res, 2011, 89(1):64-70

PubMed: 21094187

Biochim Biophys Acta, 2016, 10.1016/j.bbagen.2016.05.011

PubMed: 27180173

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025

Biochem Pharmacol, 2012, 84(4):425-31

PubMed: 22634404
J Biol Chem, 2013, 288(48):34930-42

PubMed: 24142702

Colloids and Surfaces B: Biointerfaces, 2014, 123:61-7

PubMed: 25216919

J Immunother, 2011, 34(4):372-81

PubMed: 21499124

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed:

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896

Drug Metab Dispos, 2014, 42(3):318-22

PubMed: 24335466

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131

Drug Metab Dispos, 2013, 10.1124/dmd.113.054189

PubMed: 24335466

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168

Prostate, 2013, 73(13):1453-61

PubMed: 23765757

Int J Oncol, 2012, 41(3):869-75

PubMed: 22752005

Exp Cell Res, 2016, 344(2):194-200

PubMed: 27180268
Cell Cycle, 2014, 13(24):3808-17

PubMed:

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447

Am J Physiol Renal Physiol, 2014, 307(4):F435-44

PubMed: 24990892

Eur J Pharmacol, 2017, 821:21-28

PubMed: 29277715

Oncol Rep, 2017, 37(2):1212-1218

PubMed: 27959426

Cancer Chemoth Pharm, 2014, 74(3):511-20

PubMed: 25038613

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109

PLoS One, 2014, 9(4):e93651

PubMed: 24695557

PLoS One, 2014, 9(4):e95243

PubMed: 24743578

PLoS One, 2014, 9(12):e114000

PubMed: 25486409

PLoS One, 2014, 9(5):e97719

PubMed: 24874286

PLoS One, 2013, 8(12):e82625

PubMed: 24349321
PLoS One, 2012, 7(9):e42441

PubMed: 22957020

PLoS One, 2012, 7(12):e51549

PubMed: 23272116

Mol Biosyst, 2011, 7(12):3223-33

PubMed: 21956701

Horm Cancer, 2014, 289(24):17195-202

PubMed: 24778185

Exp Mol Pathol, 2014, 97(1):154-165

PubMed: 24984270

Exp Mol Pathol, 2013, 94(2):386-97

PubMed: 23399805

Exp Mol Pathol, 2011, 91(1):400-10

PubMed: 21565184

Langenbecks Arch Surg, 2014, 10.1007/s00423-014-1235-1

PubMed: 25070024

Vet Comp Oncol, 2011, 11(2):124-39

PubMed: 22235915

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725
Int J Radiat Oncol Biol Phys, 2015, 10.1016/j.ijrobp.2015.01.026

PubMed: 25823448

Int J Radiat Oncol Biol Phys, 2014, 88(4):947-54

PubMed: 24606853

University of Alberta, 2014, Yahya Muhammad Fiteih

PubMed:

Guangxi Medical University, 2014, Suning Huang

PubMed:

JBUON , 2014, 19(2): 466-473

PubMed:

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933

Oncotarget, 2012, 2(12):1134-44

PubMed: 22193779

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388

客户使用该产品的14个实验数据：

c, HCC4006 lung cancer cells that have acquired a high-mesenchymal state concomitant with becoming resistant to gefitinib (red curve) exhibit increased sensitivity to GPX4 inhibition.

Nature, 2017, 547(7664):453-457. Gefitinib (ZD1839) purchased from Selleck.

Perturbation of EGFR by its ligand EGF and gefitinib (ZD-1839 Iressat; inhibits EGFR) produces opposite responses in the predicted EGFR target genes SOCS2 and NR2E1.

Mol Syst Biol 2011 7, 486. Gefitinib (ZD1839) purchased from Selleck.
Effects of shRNA-mediated RECK depletion on EGFR signaling in MEFs. (a) Immunoblotting (IB) of the indicated proteins in wild-type MEFs transduced with the indicated shRNAs and cultured for 48 h in the presence of 0.1% dimethyl sulfoxide (DMSO; vehicle) or 1 mM gefitinib (S1025, Selleck Chemicals,Houston, TX, USA). (b) Immunoprecipitation from whole lysates of cells from panel a with an anti-phosphorylated tyrosine (pTyr) antibody. Precipitates from 500 mg protein in whole cell lysates (upper) or 20 mg protein in whole cell lysates (lower) were analyzed by IB with anti-EGFR antibody.

Oncogene 2010 30, 737-750. Gefitinib (ZD1839) purchased from Selleck.

(B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 lM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

Carcinogenesis 2010 31, 1948–1955 . Gefitinib (ZD1839) purchased from Selleck.
LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

Carcinogenesis 2010 31, 1948–1955. Gefitinib (ZD1839) purchased from Selleck.

Suppression of EGFR signaling by Gefitinib is dose dependent and non- toxic at millimolar concentrations.Results from plaque reduction tests of Hep2 cells infected with VACV(12.5pfu/well) treated with a serial dilution of Gefitinib (1000-0.01 m) and analyzed for (A)proliferation as indicator of cytotoxicity,(B) IC50 of plaque size inhibition, (C)dose dependent inhibition of EGFR-ERK1/2signaling and VACV proteins by Western blot analysis (pEGFR detection was obtained from a different experiment with identicals ettings) and (D)dose dependent inhibition of orthopoxvirus genome replication by real-time PCR.Untreated VACV infectedcells and uninfected cells are shown as controls in the right panel.

Antiviral Res 2010 89, 64-70. Gefitinib (ZD1839) purchased from Selleck.
A circular zone of EGFR activated but uninfected cells facilitate virus induced plaque development , efficiently blocked by Gefitinib. (A)Immun of luorescent staining of aplaque reduction tests with Hep2 cells 24,48,72 and 96 h after VACV infection (6.25pfu/chamber). VACV infected cells(green) were visualized by human IgG directed to orthopoxviruses (VIG) detected with a secondary FITC labelled antibody. Uninfected cells with activated EGFR signaling(red) are detected with a secondary Cy3labelled antibody. Positive cells for both , VACV and phosphorylated EGFR are shown in yellow(merge). Cellular nuclei are counterstained with DAPI. (B)Immunofluorescent staining of a plaque reduction test as described for (A) and treated with three different Gefitinib concentrations (1000 nM, 1 nM, and 0.01 nM) . The test was analyzed 96h afterVACV infection.Uninfected cells are shown as controls. Magnification100×.(For interpretation of the references to color in this figure legend , the reader is referred to the web version of the article.)

Antiviral Res 2010 89, 64-70. Gefitinib (ZD1839) purchased from Selleck.

Susceptibility of lung cancer cells to cytolytic activity of NK-92 cells after treatment with EGFR inhibitors. Three lung cancer cells were untreated (open circle) or treated with 10 μM erlotinib or gefitinib (black filled square or black filled triangle) for 24 hours. The lung cancer cells were cocultured with NK-92 cells at indicated effector to target ratio (E:T ratio). To determine the specificity of NKG2D-mediated cytolysis of lung cancer cells, NK-92 cells were preincubated with blocking mAb against NKG2D before the assay (gray filled square and triangle) and correspond-ing isotype mAb (open square and triangle).

J Immunother 2011 34(4), 372-81. Gefitinib (ZD1839) purchased from Selleck.
Inhibition of 5-HT-induced 5-HT3A and 5-HT3AB receptor currents.

Eur J Pharmacol, 2017, 821:21-28. Gefitinib (ZD1839) purchased from Selleck.

The EGF-dependent increased association of PCM1 and AZI1 requires EGFR kinase activity. ZD1839 (Iressa)—EGFR tyrosine kinase inhibitor.

Mol Biosyst 2011 7, 3223-33. Gefitinib (ZD1839) purchased from Selleck.
Reduction of GPER expression in HCC1806 cells after treatment with gefitinib. (A) Concentration dependence. HCC1806 cells were treated with 50-500 nM gefitinib for 48 h. GPER was detected by western blotting. (B) Time dependence. HCC1806 cells were treated with 200 nM gefitinib for 24-96 h. ^ap<0.05 vs. control; ^bp<0.001 vs. control. Mean values and SE of three independent experiments are shown. (C) Representative western blotting of concentration dependence. (D) Representative western blotting of time dependence

Oncol Rep, 2017, 37(2):1212-1218. Gefitinib (ZD1839) purchased from Selleck.

Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

Int J Proteomics 2011 215496. Gefitinib (ZD1839) purchased from Selleck.
Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of Gefitinib for 24 hours.

2010 Dr. Zhang of Tianjin Medical University. Gefitinib (ZD1839) purchased from Selleck.

MTT assay result. 0-500nM Gefitinib treated with H1299, H358, H25 and HCC827 cell lines by 72h, Proliferation rate was tested.

2010 Dr. Vicky Tin from University of Hong Kong. Gefitinib (ZD1839) purchased from Selleck.

产品安全说明书

EGFR抑制剂选择性比较

生物活性

产品描述

Gefitinib (ZD1839)是一种EGFR抑制剂，作用于NR6wtEGFR和NR6W细胞中的Tyr1173，Tyr992，Tyr1173和Tyr992，IC50 分别为37 nM，37nM，26 nM和57 nM。

特性

Gefitinib是有效的EGFR酪氨酸激酶抑制剂。

靶点

Tyr1173 (NR6W cells) ^[1]	Tyr1173 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6W cells) ^[1]
26 nM	37 nM	37 nM	57 nM

体外研究

Gefitinib 作用于高和低表达EGFR的细胞系，包括NR6, NR6M 和 NR6W 细胞系，有效抑制EGFR上全部酪氨酸磷酸化位点。磷酸化位点 Tyr1173和Tyr992敏感性较低，需要高浓度Gefitinib才能抑制。Gefitinib作用于NR6W细胞，高效阻断PLC-γ磷酸化, IC50为27nM。NR6wtEGFR 和NR6M细胞系具有低水平PLC-γ磷酸化， IC50 分别为 43 nM和 369 nM。Gefitinib抑制AKT磷酸化，作用于低EGFR和EGFRvIII表达的细胞系， IC50 分别为220 和263nM。Gefitinib按 0.1 到 0.5μM剂量处理，显著促进而不是废除 NR6M细胞形成集落。然而, 2μM Gefitinib 完全抑制 NR6M 集落形成。Gefitinib 作用于高和低EGFR表达的细胞系，EGF 刺激72小时后，快速抑制EGFR 和ERK 磷酸化，这种作用存在剂量依赖性。^[1]Gefitinib抑制 EGF驱动的未转化MCF10A 细胞生长，IC50为 20 nM。^[2] Gefitinib 作用于MDA-MB-231细胞，抑制EGF信号。Gefitinib严重抑制细胞数的增多，这种作用存在剂量依赖性。 ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KB	NIPhdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TkSmlEPTB;MD6wOVQh\|ryP	MmPYNVY2OTZ2N{O=
NIH3T3	MkTFSpVv[3Srb36gRZN{[Xl?	NIm0bGExNjJizszN	MYeyJIg>	NHrFNXBFVVOR	MknqTY5pcWKrdHnvckBw\iCHR1[gd5RqdXWuYYTl[EBpfW2jbjDldoJDOSCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjBzNESg{txO	NGr0NWwyPjR6MEK4OC=>
COS7	M3H1SmZ2dmO2aX;uJGF{e2G7	MXq5OkDPxE1?			NX7pWm1mUW6qaXLpeIlwdiCxZjDoeY1idiCMQVuyJHY3OTeIIH31eIFvfCCneIDy[ZN{\WR?	M1:3OlE4OTd6N{Ky
A549	NIHEW4JEgXSxdH;4bYMhSXO\|YYm=		NWLmUllNQTZiaB?=	Mnj1SG1UVw>?	NXmxZ21NUUN3ME2xN{42QSEQvF2=	NYTuOmdvOTh\|MUO4NFc>
K562	MV7DfZRwfG:6aXOgRZN{[Xl?		M1W5b\|k3KGh?	NF\t[mtFVVOR	NUm5VItbUUN3ME25MlM3KM7:TR?=	MUOxPFMyOzhyNx?=
MDA-MB-231	Ml;6R5l1d3SxeHnjJGF{e2G7		M1nodFk3KGh?	NH21Z2ZFVVOR	M2fLXGlEPTB;M{[uOlEh\|ryP	MkXsNVg{OTN6MEe=
MOLT4	MmTGR5l1d3SxeHnjJGF{e2G7		MXK5OkBp	MWnEUXNQ	M{DKVGlEPTB;MUWuNFIh\|ryP	M3;wdVE5OzF\|OEC3
MCF7	Mk[4R5l1d3SxeHnjJGF{e2G7	M3q1dFUxKM7:TR?=	MWm3NkBp		MXvJR\|UxRTF{LkC1JO69VQ>?	MlPNNVg4PzF6MUm=
BT474	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEf1XW84OiCq		MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEKWNEe0JINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKEWUQnKyJJdqfGhiRVO1NEBw\iByLkOg{txO	NUjONIcxOTlyMki0NlQ>
HN5	NHrjfpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGrCSHA4OiCq		M{\Oc2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSF61JINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKEWJRmKge4l1cCCHQ{WwJI9nKDBwMEGg{txO	NFXQSIIyQTB{OESyOC=>
BA/F3	M3;MbmN6fG:2b4jpZ{BCe3OjeR?=		NGHsVVU4OiCq		MoTMR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCHR1\SJGw5PTiUIH31eIFvfCC5aYToJGlEPTBib3[gNE4xOTB6IN88US=>	MnLGNVkzOzl{Mkm=
NIH3T3	M3z5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoTkO\|IhcA>?		M1;lZWdzd3e2aDDpcohq[mm2aX;uJI9nKG2xdYPlJG5KUC9\|VEOgZ4VtdHNiZYjwdoV{e2mwZzDldmIzKGenbnWge4l1cCCLQ{WwJI9nKDBwNUSg{txO	NX31ZnJZOTl4NkWzO\|c>
MCF7 MX	MoLHSpVv[3Srb36gRZN{[Xl?		NWfIZXpxOzBibXnu		NXPTb\|NTUW6qaXLpeIlwdiCxZjDCR3JRKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNU4yKM7:TR?=	NX7y[JhDOTl7M{K5OlA>
A431	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWSxNEDPxE1?	NIm1V\|I4OiCq		NHPyTYtIUTVyPUCuOVE1KM7:TR?=	NWXIO4piOTl7Nkm0OlU>
A431	NEWyS\|JMcW6jc3WgRZN{[Xl?	NFjzU5oxNjFizszN	NHzrU2EyKGh?		MX;Jcohq[mm2aX;uJI9nKEWJRj3pcoR2[2WmIFXHSnIheGixc4Doc5J6dGG2aX;u	M{LpUFE6QTZ7NE[1
A431	M{X2PWtqdmG\|ZTDBd5NigQ>?	MUCxNFAh\|ryP	MYqxNEBucW5?		M{\rdnBzd2yxbnfl[EBqdmirYnn0c5J6KGGldHn2bZR6KG:oIFXHSk1qdmS3Y3XkJGVITlJicHjvd5Bpd3K7bHH0bY9v	M33GXlE6QTZ7NE[1
Sf9	NF;Fc\|VMcW6jc3WgRZN{[Xl?		NH2zb3MyOCCvaX6=	NY[4SlQzTE2VTx?=	MlPXTY5pcWKrdHnvckBw\iCHR1\SJIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJJm[2WydH;yJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuNFM{KM7:TR?=	MkXVNlAxPTZ2MkW=
NCI-H1975	NHzCcpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYj2[2dZPSEQvF2=	NYruTFJsPzJiaB?=		MX\JR\|UxRThwMk[g{txO	NVS5dFVMOjBzNUG2O\|A>
NCI-H1975	NFTWUHNMcW6jc3WgRZN{[Xl?	NWDXOlE1OTBizszN			Mn[yTY5pcWKrdHnvckBw\iCHR1\SJIF2fG:yaH;zdIhwenmuYYTpc44>	NVjKd4pbOjBzNUG2O\|A>
NCI-H1975	Mki1SpVv[3Srb36gRZN{[Xl?	M2fVXFExKM7:TR?=			MkDRTY5pcWKrdHnvckBw\iCHUlLCNkBifXSxcHjvd5Bpd3K7bHH0bY9v	M4fMSlIxOTVzNkew
NCI-H1975	NVPDfJBWTnWwY4Tpc44hSXO\|YYm=	M1HOdlUh\|ryP	NYXtSYh3PDhiaB?=		MlrQTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCjc4Pld5Nm\CCjczDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4UuOw>?	MlPYNlAyPTF4N{C=
A375	NWXNOJJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUW0PEBp		NVHsPINQUUN3ME2yNE42PSEQvF2=	MnPXNlA{ODR3M{e=
SMMC7721	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVu0PEBp		NIHJNo5KSzVyPUOzMlEzKM7:TR?=	NVr1VI1iOjB\|MES1N\|c>
DU145	NWnkPJlwS3m2b4TvfIlkKEG\|c3H5		M{\QRVUh\A>?	NVfVcmJSTE2VTx?=	NVLFXnduUUN3ME20Nk4yPyEQvF2=	MnnlNlA1PjZ3NUW=
MIAPaCa2	MkfxR5l1d3SxeHnjJGF{e2G7		MUm1JIQ>	NI\4cJdFVVOR	MX;JR\|UxRTVyLk[yJO69VQ>?	MWeyNFQ3PjV3NR?=
PANC1	NHW3XYtEgXSxdH;4bYMhSXO\|YYm=		M4Ty[\|Uh\A>?	Mlr1SG1UVw>?	Mlf5TWM2OD12MD60NkDPxE1?	NUH0UYtjOjB2Nk[1OVU>
PC9	MkHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XROGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSWdHWi2mZX\pZ4lmdnRiaIXtZY4hWEN7IHPlcIx{KHerdHigSWM2OCCxZjCwMlAyPyEQvF2=	M12wV\|IyOjB6OECy
PC9	NWO1[ms5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjEPYR2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBoem:5dHitdoV{cXO2YX70JIh2dWGwIGDDPUBk\WyuczDlfJBz\XO\|aX7nJGVITlJiRUe0On9CPzVyL2S3PVBOKG23dHHueEB4cXSqIFXDOVAhd2ZiNzFOwG0>	NFfvTlgzOTJyOEiwNi=>
PC3	M4TXWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jj[lExKM7:TR?=	NHr3eWM4OiCq	MWHEUXNQ	NF\sTodKSzVyPUeuOEDPxE1?	M3KxVFIyOzV\|NUS2
MDA-MB-468	NUD6cIc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYWxNFAh\|ryP	MnywOFghcA>?	MYPEUXNQ	NEnP[GdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fS=>	M1PLSVIyPDJ7NkOy
Plasmodium falciparum					NVToNIFreUiWUzDwdo9ncWyrbneg[o9zKGmwaHnibZRwenNib3[gVIxie22xZHn1cUBn[WylaYDhdpVuKHC{b3zp[oVz[XSrb36=	M3TGR\|IyQDF5MES1
NCI-H1993	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnLOO\|IhcA>?	NV;EVHNnTE2VTx?=	M{\qPGlEPTB;MD6xJO69VQ>?	NHTyUZIzOTlzNkSzNy=>
NCI-H292	M4C4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1;URlczKGh?	M37KdWROW09?	NVjOS4pjUUN3ME2wMlAzKM7:TR?=	NWq2bnF2OjF7MU[0N\|M>
A431	NGfnVlJMcW6jc3WgRZN{[Xl?		NGDFUFAzKGh?	NVTTVmk5TE2VTx?=	NYDlZ\|FPUW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCHR1[td5RqdXWuYYTl[EBpfW2jbjDBOFMyKHerdHigTWM2OCCxZjCwMlAxOSEQvF2=	M3XlZlIzOTBzMUOy
MCF7	NUPKVnd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nGU\|ExOMLizsznM41N	NUfERZg6PDhiaB?=	MnfWSG1UVw>?	NUPTbo1uSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJI93\XKneIDy[ZN{cW6pIFXHSnIh\2WwZTD3bZRpKEmFNUCgc4YhOTJwMEWg{txO	NHfrdJczOjFzOUGzNC=>
BT474	Ml7BR5l1d3SxeHnjJGF{e2G7	MXexNEDPxE1?	NU\2OlZFPDhiaB?=		M2O0d2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KHOncoXtMZN1[XK4ZXSgbJVu[W5iQmS0O\|Qh[2WubIO=	M3Pi[lIzOTN6M{C4
MCF7	MXrDfZRwfG:6aXOgRZN{[Xl?	NYeze5hqOTBizszN	MWq0PEBp		NXjqeFg5S3m2b4TvfIlkcXS7IHHnZYlve3Ric3XyeY0ue3Sjco\l[EBpfW2jbjDNR2Y4KGOnbHzzJI93\XJvZYjwdoV{e2mwZzDFdoJDOiClZXzsdy=>	NYLSTY9COjJzM{izNFg>
HCC827	MWTLbY5ie2ViQYPzZZk>	MViwMlEzPSEQvF2=	M4fie\|I1KGh?	MWPEUXNQ	NVXk[FYyUW6qaXLpeIlwdiCxZjDFS2ZTKGSnbDDFO\|Q3NUF5NUCgcZV1[W62IGmxNFY5KGG3dH;wbI9{eGixconsZZRqd25?	MYSyNlM{QTN2Mh?=
HCC827	NFTFUFZMcW6jc3WgRZN{[Xl?	M3jMXVAvOTJ3IN88US=>	MkXuNlQhcA>?	MlXmSG1UVw>?	NX7xTIpFUW6qaXLpeIlwdiCxZjDFS2ZTKGSnbDDFO\|Q3NUF5NUCgcZV1[W62LX3l[IlifGWmIFXyb{BxcG:\|cHjvdplt[XSrb36=	MXOyNlM{QTN2Mh?=
HCC827	NEfRfZBMcW6jc3WgRZN{[Xl?	M4G2O\|AvOTJ3IN88US=>	MXeyOEBp	MVTEUXNQ	M3HHd2lvcGmkaYTpc44hd2ZiRVfGVkBl\WxiRUe0Ok1CPzVyIH31eIFvfC2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w	NFKzW\|EzOjN\|OUO0Ni=>
A431	MUTLbY5ie2ViQYPzZZk>	MlrRNVAxKM7:TR?=	M1uxXVMxKG2rbh?=		NGL3Z4tKdmirYnn0bY9vKG:oIFXHSnIh\GW{aY\l[EBnem:vIHj1cYFvKEF2M{GgZ4VtdCCvZX3idoFv\SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHCxbImtS4x2NVS7cjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFEvODhizszN	M{PvWFIzPjl6N{iy
H460	M2PHRWN6fG:2b4jpZ{BCe3OjeR?=		Moe5O\|IhcA>?		NXn0PVRXUUN3ME21MlU6KM7:TR?=	M{PQdFIzPzJ5NES5
HT-29	Mom3R5l1d3SxeHnjJGF{e2G7		NWHwUWJ3PzJiaB?=		M{jXW2lEPTB;Mz6zOkDPxE1?	M3G0TFIzPzJ5NES5
SGC7901	MlmwR5l1d3SxeHnjJGF{e2G7		MXO3NkBp		NWrUTlh1UUN3ME2xNE4zPiEQvF2=	NW\0NHNROjJ5Mke0OFk>
A498	NHGxWlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;hSmF5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOFk5KGOnbHzzJIV5eHKnc4PpcochTUeIUjDhcoQhW1KFIIfpeIghUUN3MDDv[kA5NjZizszN	M2HuflIzQDF6OES4
Calu3	MmHjR5l1d3SxeHnjJGF{e2G7	NIjq[oIyOCEQvHevcWw>	NYjiXXgzPzJiaB?=		M2P2UGlEPTB;MT62JO69VQ>?	MYeyN\|EyPjF4OB?=
FADU	MmfsR5l1d3SxeHnjJGF{e2G7	M2TibFExKM7:Zz;tUC=>	NUPmXZBzPzJiaB?=		NYrUVXFvUUN3ME2wMlA2KM7:TR?=	NUXB[\|ZyOjNzMU[xOlg>
HCC827	NWX0eohRS3m2b4TvfIlkKEG\|c3H5	NVPZWYdFOTBizsznM41N	MXi3NkBp		Ml:3TWM2OD1yLkCwNVUh\|ryP	MkLhNlMyOTZzNki=
PC9	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX2xNEDPxGdxbVy=	MXm3NkBp		NVf5N2pYUUN3ME2wMlAxOTRizszN	MoTCNlMyOTZzNki=
Sf9	M1[3VGtqdmG\|ZTDBd5NigQ>?		NVf3e2VOOSCq	NYXGfJVGTE2VTx?=	NVT6[YtHUW6qaXLpeIlwdiCxZjDoeY1idiCJU2SteIFo\2WmIFXHSnIhVDh\|NGKgcZV1[W62IHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5yMUWg{txO	MYeyN\|YyOTZ7MR?=
16HBE14o-	MlzvR5l1d3SxeHnjJGF{e2G7	MnPNNVAh\|ryP	MXi3NkBp	NHnpc45FVVOR	NVrpbZF6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hOT[KQlWxOI8uKGOnbHzzJIhiemKxcnnu[{B4cWymIIT5dIUhTUeIUjDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMUKuO\|Eh\|ryP	Ml\DNlM3Pjh2NEG=
NCI-H1975	NWrTNWRsS3m2b4TvfIlkKEG\|c3H5	NFPySHYyOCEQvF2=	M2C5VFczKGh?	MYDEUXNQ	M13iRmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGenZnn0bY5q[i2{ZYPpd5RidnRiaIXtZY4hVkOLLVixPVc2KGOnbHzzJIhiemKxcnnu[{BGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDZwOUG3JO69VQ>?	MXGyN\|Y3QDR2MR?=
16HBE	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4nLd\|czKGh?	NYH3NHUxTE2VTx?=	MkOwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiBzNljCSUBk\WyuczDlfJBz\XO\|aX7nJJdqdGRidInw[UBGT0[UIIfpeIghUUN3MDDv[kAyNjZyMTFOwG0>	NWjxZXJ7OjN5OUKzNVg>
16HBE	M1nNe2Z2dmO2aX;uJGF{e2G7	MYCxNFAh\|ryP	MmfENVUxKG2rbh?=	MofUSG1UVw>?	MmKzTY5lfWO2aX;uJI9nKG6rdILpZ{BwgGmmZTDwdo9lfWO2aX;uJIlvKGi3bXHuJFE3UEKHIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXHSnI>	M1PwXFI{Pzl{M{G4
A549	NWfVPVd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEG5WWo4OiCq	MoDMSG1UVw>?	NFHseXFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJdqdGRidInw[UBGT0[UL3utVoF{KGSncHXu[IVvfCCqdX3hckBCPTR7IHPlcIx{KHerdHigTWM2OCCxZjC0MlYzPiEQvF2=	NYKzVIJkOjN5OUKzNVg>
SH-SY5Y	NW\ze5p{S3m2b4TvfIlkKEG\|c3H5		NX;GNXVrPzJiaB?=		NVHPRnQ6UUN3ME2xPE4zOSEQvF2=	NXTxfG1vOjN6N{G5NFk>
LoVo	NXnUTWp[U2mwYYPlJGF{e2G7		NVvEcIpoOiBiaB?=	NGPXS3pFVVOR	MofyTY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yNkKg{txO	Mkf5NlM6OzB7OUS=
PC9	NYPyVld3U2mwYYPlJGF{e2G7		MnT5NkBp	NXr1Z\|lnTE2VTx?=	NVv6W3pzUW6qaXLpeIlwdiCxZjDFS2ZTKGW6b36gNVkh\GWuZYTpc44h[WO2aY\heIlv\yCvdYThcpQheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHBEQSClZXzsd{B4cXSqIFnDOVAhd2ZiMD6wNFg4KM7:TR?=	NFrKTXQzOzl\|MEm5OC=>
HCC827	MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHXBclc4OiCq		MnfwTWM2OD1yLkCxNkDPxE1?	MXyyN\|k4OzF4OB?=
A549	NHrlSIhMcW6jc3WgRZN{[Xl?	NGHONZQyKM7:TR?=	NVm0fotNOSCq	MljySG1UVw>?	NHm3N\|VKdmirYnn0bY9vKG:oIFXHSnIh[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xOzl7IN88US=>	MVeyN\|k5QDN3NB?=
A549	MlzmSpVv[3Srb36gRZN{[Xl?	MkTZNUDPxE1?	NG\DeoMyKGh?	M4DvN2ROW09?	MX3D[YxtfWyjcjD1dJRic2V?	NX\4UZNqOjN7OEizOVQ>
HCC827	M1nwZmtqdmG\|ZTDBd5NigQ>?	M2PMSFAvPSEQvF2=	MmnSNkBp	NVXMN3F6TE2VTx?=	MVTJcohq[mm2aX;uJI9nKEWJRmKgdIhwe3Cqb4L5cIF1cW:wIHnuJIdm\mm2aX7pZk1z\XOrc4ThcpQhcHWvYX6gTGNEQDJ5IHPlcIx{	MnnVNlM6QTN\|Mki=
HCC827	M1nnbGZ2dmO2aX;uJGF{e2G7	MnjsNE42KM7:TR?=	NXjXU\|NoOiCq	MkX3SG1UVw>?	NGHENHFKdmirYnn0bY9vKG:oIHOtUYV1KHCqb4PwbI9zgWyjdHnvckBqdiCpZX\peIlvcWJvcnXzbZN1[W62IHj1cYFvKEiFQ{iyO{Bk\Wyucx?=	MU[yN\|k6OzN{OB?=
HCC827	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfvTHRrOTBizszN	MVG3NkBp	NHm0NI1FVVOR	MoXCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDn[YZqfGmwaXKtd4Vve2m2aY\lJIh2dWGwIFjDR\|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDFO\|Q3KHSxIFG3OVAh\GWuZYTpc44hf2m2aDDJR\|UxKG:oIECuNFA2QDFizszN	MoPTNlQxPTN4N{S=
A431	MknrT4lv[XOnIFHzd4F6	MV6xNFAh\|ryP	MVuzNEBucW5?		MXrJcohq[mm2aX;uJI9nKEWJRmKgbY4he2inZDDt[Y1jemGwZTD2[ZNq[2ynczD3bZRpKEmFNUCgc4YhOS5zIN88US=>	NEL1cI4zPDB7NESzNi=>
BCRP-MDCK2	NIniNXJHfW6ldHnvckBCe3OjeR?=	Mm[wNU45KM7:TR?=	MYK3NkBp	NYHxN\|hnTE2VTx?=	M4XXdmlv[3KnYYPlJI9nKHCuYYPtZUBu\W2kcnHu[UBmgHC{ZYPzbY9vKG:oIFLDVnAh\XiycnXzd4lv\yC{ZYDvdpRmeiCpZX7lJGdHWA>?	NVvkTYJ5OjRzOESyNVM>
BCRP-MDCK2	Mn\oSpVv[3Srb36gRZN{[Xl?	NXXSfWF5OS56IN88US=>	MVG3NkBp	MoLhSG1UVw>?	M{THV3Jm\HWldHnvckBw\iCybHHzcYEhdWWvYoLhcoUh\XiycnXzd4lwdiCxZjDCR3JRKGW6cILld5NqdmdicnXwc5J1\XJiZ3Xu[UBITlB?	NXzzZXJnOjRzOESyNVM>
MDCK	NGTyRodEgXSxdH;4bYMhSXO\|YYm=		MVy3NkBp	M4rJbGROW09?	MXvHTVUxRTFwNEWg{txO	NEHsb5MzPDF6NEKxNy=>
MDCK2	MUjGeY5kfGmxbjDBd5NigQ>?	NXzDTZhXOS56IN88US=>	MUe3NkBp	M4TKfGROW09?	MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGJEWlBiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJGhw\WOqc4SgN\|M{PDJiYXPjeY12dGG2aX;uJJdqfGhiSVO1NEBw\iB\|LkG5JO69VQ>?	M4XkOFI1OTh2MkGz
A431	NX7M[lhrS3m2b4TvfIlkKEG\|c3H5		M3W3S\|czKGh?	M4nCdGROW09?	MmjqR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{BmgHC{ZYPzbY5oKEWJRmKge4l1cCCLQ{WwJI9nKDBwNUWg{txO	NGK3TW0zPDRzMUGyNy=>
Calu3	MnvuR5l1d3SxeHnjJGF{e2G7		NX3kT29lPzJiaB?=	M4T2VWROW09?	NYL0OHJSS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS2GudUOgZ4VtdHNiZYjwdoV{e2mwZzDISXIzKHerdHigTWM2OCCxZjCwMlk6KM7:TR?=	NV\IXXpuOjR2MUGxNlM>
KB	MUHLbY5ie2ViQYPzZZk>	MmjpNVAh\|ryP	MlTLNUBp	MWLEUXNQ	M3\XfGlvcGmkaYTpc44hd2ZiRVfGMZN1cW23bHH0[YQh[XW2b4Doc5NxcG:{eXzheIlwdiCxZjDFS2ZTKHerdHigTWM2OCCxZjCwMlAzPSEQvF2=	NGP1Z4EzPDRzMUGyNy=>
BEAS2B	NVrlU2Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXi1NEDPxE1?	MoraO\|IhcA>?	MVfEUXNQ	NIXUeYtKSzVyPUGzMlk1KM7:TR?=	M4rEPFI1PjB5NUmx
NCI-H1975	NX\jOnZpTnWwY4Tpc44hSXO\|YYm=	M{nJZVExOCEQvF2=	MVyxOVAhdWmw	NFq2OJlFVVOR	NWfJOFNGUW6mdXP0bY9vKG:oIF7PJJBzd2S3Y4Tpc44hcW5iaIXtZY4hVkOLLVixPVc2KGOnbHzzJIhiemKxcnnu[{BGT0[UIFy4OVhTN1R5OUDNJI12fGGwdB?=	NVO0VXA3OjR4MEe1PVE>
Hela	MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NW\CU3JzOjRiaB?=	NXnJcZk2TE2VTx?=	MorDTWM2OD1{Lk[3JO69VQ>?	NXLr[ZpMOjR5M{GyPFE>
HepG2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUSzUWZSOjRiaB?=	NUnLSmM{TE2VTx?=	NXvBe5BiUUN3ME22MlQzKM7:TR?=	MnLWNlQ4OzF{OEG=
Sf9	NFfBO25McW6jc3WgRZN{[Xl?		NYjC[oJwOTBibXnu	NV\WcllTTE2VTx?=	MVTJcohq[mm2aX;uJI9nKGG3dH;wbI9{eGixconsZZRqd25ib3[gdoVkd22kaX7hcpQhcGm\|LYTh[4dm\CCHR1\SJEhidWmwbzDhZ4llKDZ2NT2xNVg3MSCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFAvODJizszN	M1vGcVI1PzNzMkix
SW620	NES4[3BEgXSxdH;4bYMhSXO\|YYm=		NXn1cYROPDhiaB?=	NHPVVppFVVOR	M3voXGlEPTB;MkiuNkDPxE1?	M{m2O\|I1QTByNUm0
HCC827	MXPGeY5kfGmxbjDBd5NigQ>?	NX:5OHdiOC53IN88US=>	MXKyJIg>	M2TJdWROW09?	NULyRW44\G:nczDuc5QhcW6qaXLpeEBkNU2ndDDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFHLWEBxcG:\|cHjvdplt[XSrb36=	MlHCNlM6QTN\|Mki=
HCC827	NECxS2JHfW6ldHnvckBCe3OjeR?=	M3PyNFAvPSEQvF2=	NF;0Z4QzKGh?	NXraNpJiTE2VTx?=	M3HSToRw\XNibn;0JIlvcGmkaYSgZ{1O\XRiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyNESvOFIheGixc4Doc5J6dGG2aX;u	NFnRSWszOzl7M{OyPC=>
HCC827	MWLDfZRwfG:6aXOgRZN{[Xl?	MXWwMlUh\|ryP	MXW3NkBp	NH:3fFhFVVOR	MlPtbIF{KG6xIHP5eI91d3irY3n0fS=>	MXiyN\|k6OzN{OB?=
NCI-H1975	NYjtW\|h4TnWwY4Tpc44hSXO\|YYm=	NVq5XVI{OTBizszN	M3TCeVghcA>?	Ml[xSG1UVw>?	MkGx[I9meyCwb4SgbY5pcWKrdHmgSWdHWiCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hTVKNIIDoc5NxcG:{eXzheIlwdg>?	NH\4SnMzOzFzNkG2PC=>
A431	MlLST4lv[XOnIFHzd4F6	MVSxJO69VQ>?	MkS1NUBp	NHuxc3lFVVOR	M3XxeohieyCwbzDpdpJmfmW{c3nicIUhcW6qaXLpeIlwdiCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25?	NFPFT\|czPDlyMEW5OC=>
LNCaP	NEXVZmZHfW6ldHnvckBCe3OjeR?=	NGn1eGgyOCEQvF2=	M{faUVJpKG:{IESgbC=>	MnvMSG1UVw>?	M3PIbIRw\XNibn;0JIlvcGmkaYSgZZV1d3Cqb4PwbI9zgWyjdHnvckBw\iCrbX31co9xfXKrZnnl[EBndGGpLYTh[4dm\CCEbYigZZN{\XO\|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcOzKSXVHUVC=>	NXzjV5RzOTh4NkezNVI>
H1975	MXjLbY5ie2ViQYPzZZk>	NFmzclAyKM7:TR?=	MY[yOEBp	NF;6WlZFVVOR	NVLx[JpD\G:nczDuc5QhcW6qaXLpeEBGT0[UIIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCKMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDteZRidnR?	MnLrNlQ3ODd3OUG=
H1975	MkLXSpVv[3Srb36gRZN{[Xl?	MlXDNUDPxE1?	NIDDO2szPCCq	NXrPb3Q6TE2VTx?=	M173b4Rw\XNibn;0JIlvcGmkaYSgSXJMKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBJOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UO\|kxVQ>?	NEK1SpMzPDZyN{W5NS=>
HCC827	NGDMXY1McW6jc3WgRZN{[Xl?	NV;TeHc6OC5zMTFOwG0>	MUSxJIg>	NGH1bYxFVVOR	Mn;RbIF{KG6xIHnydoV3\XK\|aXLs[UBqdmirYnn0bY9vKG:oIFXHSnIh[XO\|ZYPz[YQh[XNicnXjc5Zmenlib3[gSWdHWiCjdYTvdIhwe3Cqb4L5cIF1cW:w	M2\u[FI1OTJ2OEm4
H1975	Mn7zT4lv[XOnIFHzd4F6	MXywMlM{KM7:TR?=	NXT4Vo5{OiCq	MWfEUXNQ	NYXJUGE{\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEGNVDDwbI9{eGixconsZZRqd25?	M12xeFI1OTJ2OEm4
H1975	NV3EeoRnU2mwYYPlJGF{e2G7	MXywMlM{KM7:TR?=	M{XlPVIhcA>?	MXnEUXNQ	M{DZZYRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBGWkticHjvd5Bpd3K7bHH0bY9v	MV[yOFEzPDh7OB?=
H1975	M{\wW2tqdmG\|ZTDBd5NigQ>?	MXWwMlM{KM7:TR?=	M{H6TlIhcA>?	NIW0RpJFVVOR	MmjZ[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQheGixc4Doc5J6dGG2aX;u	NIXJOWszPDF{NEi5PC=>
H1975	NEe5fXJMcW6jc3WgRZN{[Xl?	Mn\NNE4yOjVizszN	NVuzOlZHOjRiaB?=	M3;CXGROW09?	MoOx[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIH31eIFvfCC\MUC2PEBifXSxcHjvd5Bpd3K7bHH0bY9v	Mm[3NlI{Ozl\|NEK=
H1975	NUm0PHZSU2mwYYPlJGF{e2G7	M{nJelAvPSEQvF2=	NVXxXlM{OjRiaB?=	MkHFSG1UVw>?	Mkmy[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIH31eIFvfC2vZXTpZZRm\CCHcnugdIhwe3Cqb4L5cIF1cW:w	NETjU5gzOjN\|OUO0Ni=>
H1975	MX3LbY5ie2ViQYPzZZk>	NGPlUIwxNjVizszN	NIPLb5AzPCCq	M2f1SGROW09?	M1[yTYRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDteZRidnRvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?=	NFPhUpczOjN\|OUO0Ni=>
MIAPaCa2	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4Hq[VIvPSEQvF2=	Mk[3O\|IhcA>?	M4nkVGROW09?	NYDBNJd3cGG\|IH7vJIdzd3e2aDDpcohq[mm2aX;u	NG\iNW4zODR4NkW1OS=>
MIAPaCa2	NFzjU5VEgXSxdH;4bYMhSXO\|YYm=	MlLyNUDPxE1?	MUmxNEBl	M{jkOWROW09?	NGjINYhp[XNibn:gZ5l1d3SxeHnjbZR6KGG\|c3Xzd4VlKGG\|IIP1dJBz\XO\|aX;uJI9nKGOxbH;ufUBnd3KvYYTpc44>	NX21e3g{OjB2Nk[1OVU>
MIAPaCa2	NWfBfYtMSXCxcITvd4l{KEG\|c3H5	M{DhO\|ExKM7:TR?=	NU\vOldEOjSqIH;yJFQ5KGh?	M3zIWGROW09?	MnPi[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?=	NGHCV3EzODR4NkW1OS=>
MIAPaCa2	MlX3RZBweHSxc3nzJGF{e2G7	Ml;MNlAh\|ryP	NHPLUHAzPCCq	M1vnc2ROW09?	NVPLcYZX\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyClYYPwZZNmKDNiYXP0bZZifGmxbh?=	M{DSZlIxPDZ4NUW1
EoL-1	MonIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXXRWE6UUN3ME21MlE4KG6P	MW\TRW5ITVJ?
NCI-H720	NXXFZYFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvtT\|ZTUUN3ME2yOk46OiCwTR?=	M1fJPXNCVkeHUh?=
NCI-SNU-5	NVnsU5dsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3KdXB6UUN3ME2yPE4yQSCwTR?=	NEi1eJBUSU6JRWK=
EW-3	NFnFUINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnlbo1KSzVyPUS2MlA1KG6P	MVLTRW5ITVJ?
HCC2218	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUP4[GROUUN3ME21NE42QSCwTR?=	MVfTRW5ITVJ?
HuO-3N1	NUfBNVFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLDdZlKSzVyPUW2MlA6KG6P	M3TxTXNCVkeHUh?=
DB	MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTZyLkm2JI5O	MkX1V2FPT0WU
HSC-4	NFX2TWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoH0TWM2OD14MT61N{BvVQ>?	NFjWUmJUSU6JRWK=
DOK	NX:yRVlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnn3TWM2OD17Mz62NkBvVQ>?	NWq1dI5IW0GQR1XS
H9	NVrKeXVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HwWGlEPTB;MUO3MlIhdk1?	MUfTRW5ITVJ?
NCI-H292	Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTF4Mj62OkBvVQ>?	MluwV2FPT0WU
HSC-2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTF4NT61O{BvVQ>?	NYTDXWo{W0GQR1XS
LU-65	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DBTGlEPTB;MU[2MlYyKG6P	MUXTRW5ITVJ?
BV-173	NH;RNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTF6Nj61OUBvVQ>?	MUnTRW5ITVJ?
LB2241-RCC	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPR[FFKSzVyPUG5OE46OyCwTR?=	NIDERXdUSU6JRWK=
KG-1	M2Hn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTJyND6zOEBvVQ>?	MX3TRW5ITVJ?
CHL-1	NEOzdXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjlfGFKSzVyPUKwPE42OSCwTR?=	NGnvUVRUSU6JRWK=
KYSE-140	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4izRmlEPTB;MkC5Mlk3KG6P	NG\zdI1USU6JRWK=
DU-145	NWXFNJZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjDTXhsUUN3ME2yNVkvODRibl2=	M3vnNXNCVkeHUh?=
EW-13	Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTJ{NT6xJI5O	M4Tjc3NCVkeHUh?=
KYSE-450	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXflSYYyUUN3ME2yOFcvQTJibl2=	MUTTRW5ITVJ?
CAL-72	M33GWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TpSWlEPTB;Mk[4Mlc{KG6P	MYjTRW5ITVJ?
MEG-01	NYrOfHNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvSTWM2OD1{N{[uO\|Yhdk1?	MUfTRW5ITVJ?
HCE-T	NIL4bGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjXPHRKSzVyPUK3PU44QSCwTR?=	MYDTRW5ITVJ?
NCI-SNU-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrzTWM2OD1{OEOuN\|Ihdk1?	NVLw[\|ZHW0GQR1XS
CAL-27	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fuZWlEPTB;Mki5MlA5KG6P	MlPLV2FPT0WU
BALL-1	NF25eFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXv0[nZuUUN3ME2yPVcvPDJibl2=	M1fhU3NCVkeHUh?=
SBC-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTWU4FsUUN3ME2zNFcvPzlibl2=	NHzIN3JUSU6JRWK=
CAL-54	MnnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvZS2dSUUN3ME2zNVEvOjNibl2=	NIXpcXNUSU6JRWK=
TI-73	M120e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rjPWlEPTB;M{GyMlc2KG6P	MYLTRW5ITVJ?
P12-ICHIKAWA	MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nzR2lEPTB;M{K4MlA3KG6P	MYXTRW5ITVJ?
ACHN	M1POeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTQTWM2OD1\|M{GuOEBvVQ>?	NYL3VnlIW0GQR1XS
PC-14	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHScoxKSzVyPUOzN{41OSCwTR?=	MkXIV2FPT0WU
HCC1806	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTN\|Nz61NUBvVQ>?	NV;FN5VUW0GQR1XS
SK-MEL-24	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHGVXZ6UUN3ME2zN\|cvQDdibl2=	MlXIV2FPT0WU
A4-Fuk	NYj5d3dJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLmTWM2OD1\|NUCuNFIhdk1?	MofJV2FPT0WU
ECC10	MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrFXXdsUUN3ME2zOVIvQTZibl2=	Mn7uV2FPT0WU
KASUMI-1	Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTN4Nj63N{BvVQ>?	NIXuOG9USU6JRWK=
CAL-33	MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\T[GlEPTB;M{ewMlkhdk1?	NGP0N5VUSU6JRWK=
MDA-MB-175-VII	MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTN5OD64PEBvVQ>?	NW\4U3dyW0GQR1XS
NUGC-3	MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DoZ2lEPTB;NECxMlgyKG6P	NV;TTnRKW0GQR1XS
KY821	NFraWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmr6TWM2OD12MEiuOVchdk1?	MlTOV2FPT0WU
CTB-1	NFOxTIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vZNmlEPTB;NEK0MlQhdk1?	M374fHNCVkeHUh?=
DoTc2-4510	MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjqUVJKSzVyPUS0Nk4yOiCwTR?=	NEjVS\|dUSU6JRWK=
EFO-27	NGP0RphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLEVVhKSzVyPUS1OE44PCCwTR?=	NXj6XYJDW0GQR1XS
BPH-1	M4TEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXnkOWNGUUN3ME20PVEvOTZibl2=	NYTiN5Z{W0GQR1XS
KYSE-270	NHXadWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXpTWM2OD12OUiuOlUhdk1?	M{TOV3NCVkeHUh?=
HO-1-N-1	MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DRZ2lEPTB;NUC5MlI2KG6P	NI\2em9USU6JRWK=
SK-MEL-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfsTWM2OD13MUCuPVkhdk1?	MUXTRW5ITVJ?
MOLT-13	MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrR[GJKUUN3ME21NVQvQDJibl2=	NIjCW4hUSU6JRWK=
TK10	NVn2dm4zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{THS2lEPTB;NUG1MlEyKG6P	MXzTRW5ITVJ?
HN	NIrUZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HUXmlEPTB;NUG3MlM5KG6P	MUDTRW5ITVJ?
SCC-15	Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnidGJDUUN3ME21NlUvPjhibl2=	MVPTRW5ITVJ?
NCI-H358	NXHwbHVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3PVfGlEPTB;NUK3MlY3KG6P	NE\t[3NUSU6JRWK=
KYSE-180	NX\mZ3M2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHkV3VVUUN3ME21N\|AvPjJibl2=	MmS5V2FPT0WU
NCI-H82	MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPzTWM2OD13NECuOUBvVQ>?	NV7NcpltW0GQR1XS
NB7	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33sc2lEPTB;NUS2MlMzKG6P	MlTxV2FPT0WU
DSH1	NIPzN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrPTWM2OD13Nk[uPFghdk1?	M2W2NXNCVkeHUh?=
RS4-11	MofKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTV4OD61PUBvVQ>?	MlzLV2FPT0WU
CAN	NYHO[opzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXRb2pFUUN3ME21PFAvPzZibl2=	MkHNV2FPT0WU
Ca9-22	MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITkS25KSzVyPUW4PE43PCCwTR?=	Mlf3V2FPT0WU
CAL-39	NXHhWo46T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2G1V2lEPTB;NUm2MlMhdk1?	NE[3UGxUSU6JRWK=
NCI-H1623	NFTUPGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIX4cXhKSzVyPUW5PU4{PiCwTR?=	M3nsPXNCVkeHUh?=
FADU	NFHtWVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DMWWlEPTB;NkC0MlY6KG6P	MUXTRW5ITVJ?
NB69	MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWH4WJNpUUN3ME22NVQvOzVibl2=	NYDBNmExW0GQR1XS
Ramos-2G6-4C10	M3rzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmrmTWM2OD14MkGuOFYhdk1?	Mkm4V2FPT0WU
LB1047-RCC	NITOboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zwTmlEPTB;NkK1MlI6KG6P	NHnxNHNUSU6JRWK=
MV-4-11	Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrjTWM2OD14MkeuO{BvVQ>?	MVHTRW5ITVJ?
DBTRG-05MG	M33DXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTZ\|Mj6yPEBvVQ>?	NX7XdJVSW0GQR1XS
ME-180	MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDaTWM2OD14M{KuPUBvVQ>?	NIrQ[4RUSU6JRWK=
NBsusSR	NHvFWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;aTWM2OD14NE[uOVIhdk1?	NY\R[oVZW0GQR1XS
COR-L105	M{n2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfEeJlKSzVyPU[2Nk42OyCwTR?=	MmPlV2FPT0WU
ETK-1	MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfKXZQyUUN3ME22OlIvPTlibl2=	MX\TRW5ITVJ?
L-363	NFr0dG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXReWtKSzVyPU[3NU46PCCwTR?=	NVzQ[JprW0GQR1XS
LU-134-A	NYfUUW97T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTdzOT6wPUBvVQ>?	NWrPO2xWW0GQR1XS
NCI-H1770	M1rXVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHuR5hSUUN3ME23NlIvPCCwTR?=	M3jNXXNCVkeHUh?=
HAL-01	Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTd\|ND63NUBvVQ>?	NWHpSod2W0GQR1XS
COLO-684	NHvzRpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jUUmlEPTB;N{WzMlAyKG6P	Mn;kV2FPT0WU
TE-6	NH7XbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTd4ND6zNUBvVQ>?	M1nvZ3NCVkeHUh?=
A431	NULufoZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfUTWM2OD15OECuNFQhdk1?	MlnBV2FPT0WU
LU-135	MoPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXV[3pSUUN3ME23PFMvODNibl2=	NE[3cYRUSU6JRWK=
EC-GI-10	NHTIR3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHTSVVKSzVyPUe4PE42OiCwTR?=	NEXy[2pUSU6JRWK=
TE-12	NEj4XFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrrdmdmUUN3ME24NlEvOTFibl2=	NHu4bodUSU6JRWK=
LoVo	MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HQfGlEPTB;OEW5MlA3KG6P	M4nCR3NCVkeHUh?=
23132-87	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfBTWM2OD16NkSuNlghdk1?	MlntV2FPT0WU
AU565	NYTZcY8zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTOXZVKSzVyPUi2PU43KG6P	M{THRnNCVkeHUh?=
DEL	M4rOXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTPd5U6UUN3ME24O\|cvPjVibl2=	NG\HOplUSU6JRWK=
COR-L88	NFX5SXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTh6Mj6yOkBvVQ>?	MXHTRW5ITVJ?
NCI-H2126	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTh6Mj64N{BvVQ>?	NYnN[VVQW0GQR1XS
CAPAN-1	NWTPOm9RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnSeFY{UUN3ME24PFMvOjlibl2=	MWjTRW5ITVJ?
BT-474	NX;0ZWFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTl\|OD6xOEBvVQ>?	NWfjTXNMW0GQR1XS
BHY	NGDGd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLPTWM2OD17N{WuOFghdk1?	MkfxV2FPT0WU
HT-3	NWjD[2loT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDJO\|lIUUN3ME25PFIvPDFibl2=	Mlj5V2FPT0WU
SK-NEP-1	NWjvd\|F2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnXUFVqUUN3ME25PFkvPDRibl2=	MoryV2FPT0WU
MS-1	NX;LOYNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTl7ND62PUBvVQ>?	NYLq[FlzW0GQR1XS
DOHH-2	NFm2WoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13XTmlEPTB;MT6wNFAzOSEQvF2=	NFzIW5pUSU6JRWK=
NCI-H1304	NFrwcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfLTWM2OD1zLkCxOlQ{KM7:TR?=	NHLCZ21USU6JRWK=
EM-2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfMTWM2OD1zLkCzNFE3KM7:TR?=	MlvSV2FPT0WU
MHH-PREB-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEH6R2RKSzVyPUGuNFg1PTFizszN	NFvKe41USU6JRWK=
KU-19-19	M{DxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nDc2lEPTB;MT6wPFU1OSEQvF2=	Mlf5V2FPT0WU
NCI-H1648	NHjTUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTqTWM2OD1zLkGwOlE3KM7:TR?=	MWfTRW5ITVJ?
MKN1	Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTFwMkG5PFch\|ryP	MmnmV2FPT0WU
SNU-449	NYOxXJc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTFwMkKyNFgh\|ryP	M17hdXNCVkeHUh?=
OAW-42	M1W1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3TRVR2UUN3ME2xMlI4QDJ3IN88US=>	MnfHV2FPT0WU
769-P	MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTFwMke5NVgh\|ryP	NW\3W2dHW0GQR1XS
SW1088	MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TXSWlEPTB;MT6yPVYxPyEQvF2=	MXvTRW5ITVJ?
GCIY	NH\4UIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmC0TWM2OD1zLkOwNVMzKM7:TR?=	NVTZTmd3W0GQR1XS
CTV-1	NH3VXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XFXGlEPTB;MT6zNFgh\|ryP	NWr3[I46W0GQR1XS
NCI-H1092	NWjLPGNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPzSJRbUUN3ME2xMlMxQDVizszN	M1v4TnNCVkeHUh?=
NKM-1	NHfyZVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInYSHhKSzVyPUGuN\|I2QTdizszN	NGPZd\|dUSU6JRWK=
NCI-H1650	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;TR2lEPTB;MT6zN\|Q5OiEQvF2=	MlP2V2FPT0WU
SW954	MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPofZV4UUN3ME2xMlM1ODR6IN88US=>	NWqxXWdyW0GQR1XS
SW48	MmG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLuTWM2OD1zLkO2OlE5KM7:TR?=	NEjvcJBUSU6JRWK=
SK-N-DZ	NEDnSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTFwM{[5OFch\|ryP	MnTQV2FPT0WU
KMOE-2	MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTFwM{m4NVUh\|ryP	M{j5fXNCVkeHUh?=
NB5	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7JTWM2OD1zLkSwPFk1KM7:TR?=	MWfTRW5ITVJ?
CCRF-CEM	M4i2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DXfmlEPTB;MT60NVEyKM7:TR?=	NGrpSlNUSU6JRWK=
RH-1	M3;uTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTFwNEGxN\|Yh\|ryP	MnnVV2FPT0WU
NCI-H526	NUTYeWo1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV63U5hmUUN3ME2xMlQ{QDJ4IN88US=>	MkHqV2FPT0WU
697	M4HQfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFraRZBKSzVyPUGuOFQyODRizszN	NEPjfI5USU6JRWK=
J82	M4TS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfhdFNKSzVyPUGuOFU4PjZizszN	MljmV2FPT0WU
BE-13	NXfIe2g4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPtTWM2OD1zLkWwOlcyKM7:TR?=	NXvpOZc5W0GQR1XS
SAS	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrvSlJyUUN3ME2xMlUyPjJ{IN88US=>	MVvTRW5ITVJ?
SCC-25	M3PRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1eyOmlEPTB;MT61NlMzOiEQvF2=	M1;2O3NCVkeHUh?=
LAMA-84	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjLV2hIUUN3ME2xMlU{QDF3IN88US=>	NFTvRotUSU6JRWK=
HSC-3	MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPOTI5TUUN3ME2xMlU1OzhizszN	MVXTRW5ITVJ?
BT-549	NF\ofHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTFwNUi3OFch\|ryP	NYm0OWhGW0GQR1XS
ML-2	M2XNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XINWlEPTB;MT62OFAzQSEQvF2=	NGLxS2NUSU6JRWK=
BB30-HNC	NGnR[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDOTWM2OD1zLk[4PVczKM7:TR?=	NH;TTlZUSU6JRWK=
PANC-03-27	NFPLOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37aeGlEPTB;MT63NFE{QSEQvF2=	MnfxV2FPT0WU
COLO-678	NYO5b4MzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTFwN{O0OFQh\|ryP	M4T3S3NCVkeHUh?=
NCI-H1666	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHidGZyUUN3ME2xMlc1PzB2IN88US=>	M3;jNHNCVkeHUh?=
NCI-H209	NH3DXZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zTRWlEPTB;MT63O\|I3QSEQvF2=	MkLSV2FPT0WU
EPLC-272H	NF;UNG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTFwOEW1OFkh\|ryP	NXrPOHo1W0GQR1XS
OMC-1	NH7ycmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHB[JJyUUN3ME2xMlk6QDh6IN88US=>	MULTRW5ITVJ?
HCC70	NEO2cXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknTTWM2OD1{LkCwPFE2KM7:TR?=	M{W1dnNCVkeHUh?=
CAL-12T	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjXRoliUUN3ME2yMlAyQDZzIN88US=>	NGn2b3ZUSU6JRWK=
TGBC24TKB	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTJwMEK5OlEh\|ryP	MkXrV2FPT0WU
EKVX	MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTJwMES5N\|kh\|ryP	MkLOV2FPT0WU
SW1116	NX;MfYVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1PYUmlEPTB;Mj6wOlAxQSEQvF2=	NYf5ZXJ1W0GQR1XS
NCI-H2009	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTJwME[yNVQh\|ryP	Mmr0V2FPT0WU
RPMI-8866	NHmxXHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTlTWM2OD1{LkC4OFgyKM7:TR?=	NGfXcWRUSU6JRWK=
KARPAS-45	NVnYTHp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXGTWM2OD1{LkGyOFc6KM7:TR?=	MnXJV2FPT0WU
RXF393	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTJwMUOwN\|Yh\|ryP	NIGyW4xUSU6JRWK=
786-0	NF\pZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rDVWlEPTB;Mj6xPFQxPiEQvF2=	MVnTRW5ITVJ?
SCC-4	Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXwTWM2OD1{LkKxO\|c3KM7:TR?=	NYTOdo9LW0GQR1XS
BT-20	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn64TWM2OD1{LkK2O\|Q1KM7:TR?=	MWLTRW5ITVJ?
A498	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{njPGlEPTB;Mj6yPVQyPSEQvF2=	NVzuPG06W0GQR1XS
IGROV-1	NFPMXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX60WYE1UUN3ME2yMlMyOjN5IN88US=>	MXfTRW5ITVJ?
JVM-3	NWW3V\|JmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlryTWM2OD1{LkO0OlQ{KM7:TR?=	NEWwWlBUSU6JRWK=
NCI-H2170	MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHvTWM2OD1{LkO0O\|g{KM7:TR?=	MnT4V2FPT0WU
EW-18	MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zOTWlEPTB;Mj6zOVQ4OSEQvF2=	MmCyV2FPT0WU
KU812	M2nPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXsZZZKSzVyPUKuN\|Y4PzlizszN	NUX4SoZ4W0GQR1XS
NY	NID6Nm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoS4TWM2OD1{LkO3Nlch\|ryP	M4LGPXNCVkeHUh?=
HTC-C3	NUjxfpIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfOTWM2OD1{LkSyNlY4KM7:TR?=	Mn3RV2FPT0WU
CFPAC-1	MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTJwNEO4OlQh\|ryP	NV;1V457W0GQR1XS
HH	NIe3PVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jwZmlEPTB;Mj60PVg2PCEQvF2=	NWfUfXlSW0GQR1XS
MKN7	NHi1boJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXDUYJKSzVyPUKuOlI4PDhizszN	MkPTV2FPT0WU
TE-8	NGj0U5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUO5TphQUUN3ME2yMlY{PjV\|IN88US=>	Mn3XV2FPT0WU
MC-IXC	Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPvTWM2OD1{Lk[0OFU{KM7:TR?=	MVLTRW5ITVJ?
DMS-79	NIXwUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXtdYpKSzVyPUKuOlkzQDRizszN	M4nI[nNCVkeHUh?=
Detroit562	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLuZmFwUUN3ME2yMlY6QDR3IN88US=>	NH[4bVZUSU6JRWK=
HuP-T4	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\tTWM2OD1{LkeyPFE5KM7:TR?=	NH3IU25USU6JRWK=
QIMR-WIL	NHy5cIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnoNplKSzVyPUKuO\|U6PTJizszN	MW\TRW5ITVJ?
BB65-RCC	M1\JZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTJwOEC3NVMh\|ryP	NVrZXWU3W0GQR1XS
PC-3	M1G3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVj1Z3JyUUN3ME2yMlg{OzF5IN88US=>	MoTIV2FPT0WU
OVCAR-3	NF7VfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTJwOEW1PVQh\|ryP	M3vKS3NCVkeHUh?=
KYSE-510	NXrXR3VKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHm5e2lKSzVyPUKuPFY4QDZizszN	M2D2WHNCVkeHUh?=
HC-1	NX73c2o{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTJwOUSwNVIh\|ryP	M3fFZ3NCVkeHUh?=
NCI-H1693	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7rfJB5UUN3ME2yMlk2QDl5IN88US=>	MnfpV2FPT0WU
DU-4475	NY\GU4c2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPNTWM2OD1{Lkm5NFUzKM7:TR?=	M{XzOXNCVkeHUh?=
COLO-680N	M2njd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTNwMEC0PVUh\|ryP	MmThV2FPT0WU
MN-60	NEnucVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;idGlEPTB;Mz6wOFk4PCEQvF2=	Mmf2V2FPT0WU
BCPAP	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{G4W2lEPTB;Mz6wPFI6PSEQvF2=	M3\y[HNCVkeHUh?=
647-V	NUL5XWg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TRdWlEPTB;Mz6xOlIzKM7:TR?=	MX3TRW5ITVJ?
HT-1376	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jZfGlEPTB;Mz6yNFUxPiEQvF2=	MkHFV2FPT0WU
NCI-H1793	NGXuTplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDTPHRKSzVyPUOuNlExQThizszN	MonsV2FPT0WU
SW1463	M1S1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYm0XJRkUUN3ME2zMlI3OTl{IN88US=>	M4XpZnNCVkeHUh?=
NCI-H727	MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LyUmlEPTB;Mz6zPFU5PCEQvF2=	NXXvb5NYW0GQR1XS
LB771-HNC	MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;oVGlEPTB;Mz6zPVEzPiEQvF2=	M{DO[nNCVkeHUh?=
D-542MG	Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XV[WlEPTB;Mz60OFIzOiEQvF2=	MXLTRW5ITVJ?
NTERA-S-cl-D1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XGOWlEPTB;Mz60OFk2PyEQvF2=	M3Xsb3NCVkeHUh?=
C8166	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jHdmlEPTB;Mz60OlUzOSEQvF2=	MVHTRW5ITVJ?
639-V	NXy1dmtxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17XS2lEPTB;Mz61O\|c6OiEQvF2=	M4O2NXNCVkeHUh?=
TE-1	MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTNwNUmxOlkh\|ryP	MYLTRW5ITVJ?
OAW-28	NVO1RZB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmCxTWM2OD1\|LkW5OFI3KM7:TR?=	MVzTRW5ITVJ?
SK-LU-1	M1K3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDYflhKSzVyPUOuOlA3PDVizszN	NH3jfYxUSU6JRWK=
CaR-1	NWLmS3RRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnz6TWM2OD1\|Lk[xNFQ5KM7:TR?=	M1XGOnNCVkeHUh?=
A2780	NFvrVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEW1ZlhKSzVyPUOuOlQxQDlizszN	NYDxSGp4W0GQR1XS
C2BBe1	MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\XTWM2OD1\|Lk[0OFA4KM7:TR?=	MlLxV2FPT0WU
SK-MES-1	NE\udFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnnTWM2OD1\|Lk[0OlE1KM7:TR?=	NWDUO5F6W0GQR1XS
PANC-10-05	MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nHfWlEPTB;Mz63NlA4OiEQvF2=	Mk\iV2FPT0WU
J-RT3-T3-5	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTNwN{W0NFYh\|ryP	MlXxV2FPT0WU
ES4	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUe4[GNUUUN3ME2zMlgzOjh4IN88US=>	MoLPV2FPT0WU
NCI-H28	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PJRWlEPTB;Mz64Nlk3OSEQvF2=	M1radHNCVkeHUh?=
NCI-H1155	NIDIWmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTNwOESxOVkh\|ryP	Mn\QV2FPT0WU
KURAMOCHI	NE\RWmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTNwOE[wOVYh\|ryP	MXnTRW5ITVJ?
NCI-H69	NF7iXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETNWFRKSzVyPUOuPVAyPzhizszN	NH;nb2NUSU6JRWK=
IST-MES1	MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTNwOUSwNlkh\|ryP	MXvTRW5ITVJ?
NH-12	Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4W0XmlEPTB;Mz65OFE5PyEQvF2=	M3:5fnNCVkeHUh?=
JVM-2	NUHLXWRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTGTWM2OD1\|Lkm0O\|UzKM7:TR?=	MlntV2FPT0WU
EW-16	NInrZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfxNod4UUN3ME2zMlk2PTd5IN88US=>	NEfLWlBUSU6JRWK=
NCI-H441	M160Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PKSWlEPTB;Mz65O\|AyPCEQvF2=	NFPYc4VUSU6JRWK=
RCC10RGB	M4PMbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTRwMEGyOFYh\|ryP	MojvV2FPT0WU
TCCSUP	M2T2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jBXmlEPTB;ND6xNVA2KM7:TR?=	MYPTRW5ITVJ?
HL-60	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7FTWM2OD12LkGyNlQyKM7:TR?=	MoLhV2FPT0WU
EW-11	NXfKe\|E5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXzUYNKSzVyPUSuNVMzPjFizszN	NXHmfI9kW0GQR1XS
KARPAS-299	NFq3OIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY[2S3FOUUN3ME20MlMyODF\|IN88US=>	NXTGNGNuW0GQR1XS
SNU-C2B	M1X6b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLhcHBOUUN3ME20MlM1Pjh4IN88US=>	Ml\4V2FPT0WU
LU-139	MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknvTWM2OD12LkO3NlQ4KM7:TR?=	NGG1TpdUSU6JRWK=
HCC1937	MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTRwM{e5PVMh\|ryP	MYLTRW5ITVJ?
GR-ST	M1vVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLJO\|JKSzVyPUSuOFMyQCEQvF2=	NX;5UZFTW0GQR1XS
SK-OV-3	M1jPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXr2UXFCUUN3ME20MlQ3ODR{IN88US=>	M1fubXNCVkeHUh?=
A172	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTRwNUW1NlEh\|ryP	MnPxV2FPT0WU
NB10	NEOzZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3WycGlEPTB;ND61PVc5OSEQvF2=	NH;xcmdUSU6JRWK=
P30-OHK	MkHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTRwOEG5Nlkh\|ryP	NFXHR29USU6JRWK=
KYSE-520	NGDjXJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fVU2lEPTB;ND64PFAyQCEQvF2=	M17UdHNCVkeHUh?=
KNS-62	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFq5[ZFKSzVyPUSuPVA5ODdizszN	Ml7SV2FPT0WU
ES1	NHX5UoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXmTWM2OD12Lkm2NFM2KM7:TR?=	NVzle3hCW0GQR1XS
KOSC-2	NUSzOm9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\KTWM2OD12Lkm5PVU6KM7:TR?=	NVGw[VdyW0GQR1XS
TE-9	MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\4SodKSzVyPUWuNFE2OjVizszN	M1zvZ3NCVkeHUh?=
NCI-H1838	M{\BTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXrR2luUUN3ME21MlAzODd4IN88US=>	MYfTRW5ITVJ?
KP-N-YN	M4HSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnz1TWM2OD13LkGyOVkyKM7:TR?=	M2nGbnNCVkeHUh?=
ALL-PO	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTVwMkK1PFch\|ryP	NUXzUHpLW0GQR1XS
NOMO-1	NEeye2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\vTWM2OD13LkKzNVc3KM7:TR?=	M1\1bXNCVkeHUh?=
CGTH-W-1	NIXmbHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTI[XVVUUN3ME21MlM5PTh2IN88US=>	NIrFdFRUSU6JRWK=
ATN-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3K5SmlEPTB;NT60NVE5PCEQvF2=	MYfTRW5ITVJ?
AGS	M4[zPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIj4dppKSzVyPUWuOFk3OThizszN	NWTVTVREW0GQR1XS
SW13	NG\DOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPmN21KSzVyPUWuOVMzPjVizszN	NG\VSGhUSU6JRWK=
SW1990	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnq3TWM2OD13Lk[yNlg2KM7:TR?=	NYny[IxSW0GQR1XS
BFTC-905	NUH2ZogxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXrb5VKSzVyPUWuOlU5PzhizszN	MUXTRW5ITVJ?
RMG-I	M2rNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DaSWlEPTB;NT62OVk1OiEQvF2=	M3rQUHNCVkeHUh?=
HD-MY-Z	M2fpd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4ewXWlEPTB;NT62PFU5OSEQvF2=	MYjTRW5ITVJ?
HCC1187	NFe2b41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTVwN{GwN\|Ih\|ryP	Mof2V2FPT0WU
HCC2998	MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnqbJhKSzVyPUWuO\|E5PzdizszN	NUfaN2IyW0GQR1XS
RT-112	NX\j[FlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLDTWM2OD13LkmwNlQ2KM7:TR?=	M2DkUHNCVkeHUh?=
CAKI-1	NEj3OmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTZwMEC5PFUh\|ryP	NITQbGtUSU6JRWK=
HDLM-2	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1y1S2lEPTB;Nj6wNVQ5QSEQvF2=	MWHTRW5ITVJ?
TE-10	NWXPS49nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTZwMES4N\|Mh\|ryP	NEPhNGFUSU6JRWK=
KE-37	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETDUZBKSzVyPU[uNFczPThizszN	NYnw[WhiW0GQR1XS
RCM-1	MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTZwMEe3NVkh\|ryP	MYnTRW5ITVJ?
Mewo	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\Ge3hKSzVyPU[uNVE1QDdizszN	MoLHV2FPT0WU
L-428	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPxcGdKSzVyPU[uNVgxOzdizszN	MUnTRW5ITVJ?
8-MG-BA	M4fl[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfCTWM2OD14LkG5N\|c6KM7:TR?=	M3HSbHNCVkeHUh?=
SK-MEL-28	M4W2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\6XWJPUUN3ME22MlIxQTZ5IN88US=>	NW\yS2F5W0GQR1XS
VA-ES-BJ	NYH4S4x1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTZwM{C0OlIh\|ryP	M3j1THNCVkeHUh?=
CAL-120	Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfNbHNKSzVyPU[uOFUyPjJizszN	Mo\HV2FPT0WU
GAMG	NHe0S\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHxVoVKSzVyPU[uOVA3OiEQvF2=	NIDyfIFUSU6JRWK=
MSTO-221H	M2XpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\MTWM2OD14LkWxNVch\|ryP	Mle5V2FPT0WU
GCT	NGfhOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LufGlEPTB;Nj61N\|M5PyEQvF2=	MXfTRW5ITVJ?
SH-4	Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDRTWM2OD14LkW4PFQ1KM7:TR?=	M{e5OHNCVkeHUh?=
Calu-3	MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fsfGlEPTB;Nj62OVU3QCEQvF2=	MmriV2FPT0WU
SK-HEP-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXpcJJKSzVyPU[uO\|E4PTNizszN	M4Hie3NCVkeHUh?=
PFSK-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfybpZKSzVyPU[uO\|M1PzhizszN	M4fDXXNCVkeHUh?=
NB12	MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;6SYVVUUN3ME22Mlc5PDB2IN88US=>	MmnuV2FPT0WU
A388	NGH1[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTZwOEm1NkDPxE1?	M3OxeXNCVkeHUh?=
KLE	M33nRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTZwOU[1NVYh\|ryP	NUPKN3RZW0GQR1XS
TE-11	MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXab5F3UUN3ME23MlA1QTZ5IN88US=>	MWfTRW5ITVJ?
NCI-H2405	MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrDPI5MUUN3ME23MlA5Ozl\|IN88US=>	MmXjV2FPT0WU
OVCAR-4	M2TSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTdwMUWzOUDPxE1?	M131WXNCVkeHUh?=
KP-N-YS	NXPtXI5JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DXXWlEPTB;Nz6xPFE1KM7:TR?=	MXXTRW5ITVJ?
NOS-1	NWjCUFlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTdwMkW4Nlgh\|ryP	Mkm1V2FPT0WU
DMS-114	MmDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zSd2lEPTB;Nz6yPVY{OSEQvF2=	M3exXnNCVkeHUh?=
NCI-H2030	NWDOSVVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTdwM{O2PVgh\|ryP	M1j2fHNCVkeHUh?=
HEL	NG\LWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTdwM{e1NlEh\|ryP	MmLGV2FPT0WU
CAL-62	NV;h[mVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW[0fmRYUUN3ME23MlM6QDZ4IN88US=>	MmTlV2FPT0WU
COLO-668	MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\tVJBUUUN3ME23MlQ{QTZ5IN88US=>	MnH5V2FPT0WU
SKG-IIIa	NFjBVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY[zdIM6UUN3ME23MlQ2OzhzIN88US=>	M1PRUnNCVkeHUh?=
HCC1419	NFnOZ5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3L6WGlEPTB;Nz60Olg{OyEQvF2=	NUPKRYdVW0GQR1XS
OS-RC-2	M3H6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTYTWM2OD15LkS5PFk1KM7:TR?=	NGLBcXNUSU6JRWK=
COLO-829	MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTdwNk[0OlMh\|ryP	MkXFV2FPT0WU
NB13	MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nGVWlEPTB;Nz64NlY3PyEQvF2=	NVfxc\|FMW0GQR1XS
DK-MG	NFLBdXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\LO4xKSzVyPUeuPFMzODFizszN	M3W0S3NCVkeHUh?=
SHP-77	M3rKTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPnWW96UUN3ME23Mlg3PjV\|IN88US=>	NFT4TlBUSU6JRWK=
NCI-H661	M3rnSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTKRlBJUUN3ME24MlA2QDZ5IN88US=>	MnPWV2FPT0WU
AM-38	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRThwMU[yPEDPxE1?	MVrTRW5ITVJ?
VM-CUB-1	NX3OeIFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVThc5hzUUN3ME24MlE4ODJ7IN88US=>	NYf1XlNmW0GQR1XS
KYSE-70	NIDrVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnzNodSUUN3ME24MlE6PzZzIN88US=>	MmHxV2FPT0WU
5637	NX;wOGdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{L3RWlEPTB;OD6zNVA2PSEQvF2=	MoLNV2FPT0WU
TGBC11TKB	NEGyRnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7zd2ZKSzVyPUiuOFYyPjRizszN	NFH4b\|VUSU6JRWK=
EGI-1	NIHNToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M32wSGlEPTB;OD62NFA5QCEQvF2=	MmjBV2FPT0WU
D-392MG	M1:yT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;nd2lEPTB;OD62OlIyPCEQvF2=	NHnVS4VUSU6JRWK=
A673	NEjEUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zSSGlEPTB;OD62O\|YyOSEQvF2=	NFfqVHNUSU6JRWK=
COLO-792	NYfEXpo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEX4S3FKSzVyPUiuO\|Q6PDZizszN	NGX1cmVUSU6JRWK=
NCI-H1792	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nLemlEPTB;OD64PFkxOyEQvF2=	NHjm[FNUSU6JRWK=
LS-1034	NH33O3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HUZWlEPTB;OD65OFY2OiEQvF2=	MXXTRW5ITVJ?
D-566MG	MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTlwMEG4NUDPxE1?	NEHrcHFUSU6JRWK=
NCI-H226	M2\sfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorSTWM2OD17LkC5JO69VQ>?	NWXtcphHW0GQR1XS
ChaGo-K-1	NGnVPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjiT\|g3UUN3ME25MlExPTd7IN88US=>	Mo\2V2FPT0WU
NCI-H2228	NGj0SXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUK2SIt6UUN3ME25MlEyODhzIN88US=>	NXW5WJI6W0GQR1XS
RPMI-8226	M2nKZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTlwMUGzNFQh\|ryP	MX;TRW5ITVJ?
BFTC-909	M4ryZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2CxZ2lEPTB;OT6xPFI6PyEQvF2=	M3rteXNCVkeHUh?=
HPAF-II	NYfIdpNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTlwMkK1NVgh\|ryP	NEe4fHBUSU6JRWK=
Capan-2	NYroSIx7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;LTWM2OD17LkSwNVA6KM7:TR?=	MWjTRW5ITVJ?
IA-LM	Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HESmlEPTB;OT60NVk3PiEQvF2=	MlLWV2FPT0WU
KP-4	M{S0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHrOG5KSzVyPUmuOFg5OzhizszN	NHjDRplUSU6JRWK=
A101D	MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTlwNUG3NVkh\|ryP	NHLMfoRUSU6JRWK=
EFO-21	NGDpRVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDHfYdoUUN3ME25MlU5PzN3IN88US=>	MW\TRW5ITVJ?
C32	M4Cx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfxeVBCUUN3ME25MlY{OzRizszN	MUDTRW5ITVJ?
SW837	MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHCWVI{UUN3ME25Mlg1QDJizszN	NGPCUYxUSU6JRWK=
OCI-AML2	NGXTU\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHMToFZUUN3ME25Mlg3QTZizszN	NV7mcWwzW0GQR1XS
NCI-H1355	M{Tndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7iTWM2OD17Lkm0NFg5KM7:TR?=	MXTTRW5ITVJ?
NCI-H2342	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrHbI5mUUN3ME2xNE4xOTV3IN88US=>	MmXBV2FPT0WU
A204	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7PTWM2OD1zMD6wOFY3KM7:TR?=	M1[4ZnNCVkeHUh?=
CAL-51	NFPyfnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPETWM2OD1zMD6wPFc4KM7:TR?=	M3nSUXNCVkeHUh?=
HCE-4	NUjEN2FFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\NVWlEPTB;MUCuNVEzOiEQvF2=	MnjwV2FPT0WU
NCI-H810	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXrTWM2OD1zMD6xOVk4KM7:TR?=	MY\TRW5ITVJ?
DJM-1	M2LVR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTFyLkG3N\|Ih\|ryP	M4i2dnNCVkeHUh?=
SK-UT-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHyTWM2OD1zMD6yOVc1KM7:TR?=	M37Qc3NCVkeHUh?=
U031	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTFyLkK2PFYh\|ryP	MUfTRW5ITVJ?
YH-13	M3\Mc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjmTWM2OD1zMD6zNFU4KM7:TR?=	M1X1cnNCVkeHUh?=
K5	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTFyLkOzPVUh\|ryP	M1vL[HNCVkeHUh?=
HEC-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIrxPYJKSzVyPUGwMlQxQDFizszN	MVTTRW5ITVJ?
A2058	NUfNZ4VQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTh[pp7UUN3ME2xNE42PDlzIN88US=>	MnXvV2FPT0WU
SW962	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3vTWM2OD1zMD62NlA1KM7:TR?=	NUXGOHpTW0GQR1XS
VMRC-RCZ	NHTGV2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTFyLk[3OFkh\|ryP	NWnoeJdCW0GQR1XS
D-336MG	M4SyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTFyLkewNFUh\|ryP	MkTlV2FPT0WU
LXF-289	MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTFyLke5Olch\|ryP	Mnv2V2FPT0WU
SW900	MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTFyLkiyNlgh\|ryP	M2TnTHNCVkeHUh?=
K-562	M4P6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTFyLkizPVUh\|ryP	Ml\CV2FPT0WU
HCC38	M{LTW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;ve2lEPTB;MUCuPVcyPiEQvF2=	M3PnR3NCVkeHUh?=
SF-295	NYjEU2VrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTFyLkm5NFIh\|ryP	NH7ycpNUSU6JRWK=
LB831-BLC	MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPaXWpEUUN3ME2xNU4zPTV4IN88US=>	NWTKN2JDW0GQR1XS
FTC-133	M3XoXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVWyTpUxUUN3ME2xNU4{ODhzIN88US=>	Mn[1V2FPT0WU
HCC1954	NXPjXlVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTFzLkSzOkDPxE1?	Mm[4V2FPT0WU
GOTO	MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHtXHNxUUN3ME2xNU42OjB4IN88US=>	MVjTRW5ITVJ?
LS-411N	M3LTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\XdGhKSzVyPUGxMlYyODFizszN	MnPGV2FPT0WU
RPMI-7951	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTFzLk[zOFgh\|ryP	NGHJbnlUSU6JRWK=
NCI-H1299	M4X6dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTFzLk[2OFch\|ryP	Ml;xV2FPT0WU
MLMA	MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTFzLk[5PVch\|ryP	MkXnV2FPT0WU
MMAC-SF	M3KxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTFzLkeyOVIh\|ryP	MYXTRW5ITVJ?
UM-UC-3	MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUSzT2dqUUN3ME2xNU44PDJzIN88US=>	MknkV2FPT0WU
SCC-9	M3HtNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjFN3dKSzVyPUGxMlgyPTFizszN	NGC2blZUSU6JRWK=
HOS	NEf3ZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTicoR6UUN3ME2xNU45Pjh\|IN88US=>	M3m2eXNCVkeHUh?=
OE19	MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnTWJU1UUN3ME2xNU46OzZ5IN88US=>	M{fPeXNCVkeHUh?=
Mo-T	M3ruRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTSTWM2OD1zMT65OVQyKM7:TR?=	NY\vXJk3W0GQR1XS
CAMA-1	M4r4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljxTWM2OD1zMj6xOlM{KM7:TR?=	MknZV2FPT0WU
U-118-MG	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4C1R2lEPTB;MUKuNlQ1OSEQvF2=	NEXIbFBUSU6JRWK=
KS-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTF{LkK4N\|Ih\|ryP	M3e2NHNCVkeHUh?=
JAR	MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3KTWM2OD1zMj6zN\|Y6KM7:TR?=	M{jXWXNCVkeHUh?=
ABC-1	NHroTJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTF{LkO0NUDPxE1?	NXPTUnppW0GQR1XS
Daoy	NFfx[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHSTWM2OD1zMj60OVQzKM7:TR?=	NF7ZbFlUSU6JRWK=
C3A	NVfVZnJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLPRWI5UUN3ME2xNk42Pzh3IN88US=>	MX;TRW5ITVJ?
GT3TKB	NHrBR2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DJdWlEPTB;MUKuOlMzPyEQvF2=	NEfBeohUSU6JRWK=
DMS-273	MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDYd3NKSzVyPUGyMlg3OzNizszN	NUS4PJhTW0GQR1XS
G-361	NFf5OpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTF{LkmxNlkh\|ryP	MnTvV2FPT0WU
RH-18	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\ze2Z4UUN3ME2xN{4zQTZ{IN88US=>	MmfZV2FPT0WU
SN12C	NI\mSolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\BTWM2OD1zMz6zPFA5KM7:TR?=	NXjqe\|ZZW0GQR1XS
NCI-H1993	NWT4bJdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzn[JBKSzVyPUGzMlQzQDVizszN	M3PlUnNCVkeHUh?=
LOXIMVI	MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzEN2Z2UUN3ME2xN{43OTVzIN88US=>	MWXTRW5ITVJ?
SK-PN-DW	NUDMdllqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjSTWM2OD1zMz64OFI4KM7:TR?=	M3raZnNCVkeHUh?=
KALS-1	NFyyXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nZN2lEPTB;MUOuPFUzPSEQvF2=	NGjMWlFUSU6JRWK=
LAN-6	NXXwWGhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nLUmlEPTB;MUSuNlU{KM7:TR?=	NEPLOnpUSU6JRWK=
A549	NVnKepdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorwTWM2OD1zND60O\|EzKM7:TR?=	M1nTPXNCVkeHUh?=
RD	NIXtdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXf5ZYFrUUN3ME2xOE41QDF\|IN88US=>	NYLuNI5IW0GQR1XS
TGBC1TKB	Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVi4NmxMUUN3ME2xOE43PjF3IN88US=>	MXrTRW5ITVJ?
NCI-H630	MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHm0do9KSzVyPUG0Mlk1PjdizszN	MUnTRW5ITVJ?
MIA-PaCa-2	NE[yXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITIZWZKSzVyPUG0Mlk3QSEQvF2=	MnLSV2FPT0WU
NCI-H1755	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXVbpBKSzVyPUG0Mlk6PTNizszN	MYnTRW5ITVJ?
MOLT-4	Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTF3LkC0PVch\|ryP	NUTjN4s5W0GQR1XS
CW-2	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHmZpVlUUN3ME2xOU4yPDJzIN88US=>	M3flXHNCVkeHUh?=
COLO-320-HSR	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1WwOWlEPTB;MUWuOVMxPyEQvF2=	MlPKV2FPT0WU
UMC-11	M4W4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfJfm9KSzVyPUG1Mlc2OjNizszN	MkO2V2FPT0WU
MCF7	M3OyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vLdWlEPTB;MUWuPFE1PSEQvF2=	NXXvRpJZW0GQR1XS
NCI-H23	NHnF[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPib3ZDUUN3ME2xOU45PDN6IN88US=>	MmWxV2FPT0WU
HuCCT1	NE\wSpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;4cmlEPTB;MUWuPFc1KM7:TR?=	MWfTRW5ITVJ?
MPP-89	NWnyT5RsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDFTWM2OD1zNT65OFE4KM7:TR?=	M3z2[3NCVkeHUh?=
HT55	NVvmTJhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;GfXNKSzVyPUG1Mlk1PzhizszN	M{O5TXNCVkeHUh?=
no-11	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTF3Lkm2OlMh\|ryP	NF;WcpFUSU6JRWK=
GP5d	NFzt[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7i[XNKSzVyPUG2MlIyQDdizszN	M3PaeXNCVkeHUh?=
BHT-101	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXThOnhHUUN3ME2xOk4zPDN7IN88US=>	NYn1fJRtW0GQR1XS
M059J	M{\Cfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HD[mlEPTB;MU[uNlg1KM7:TR?=	NYLjbJBjW0GQR1XS
D-283MED	MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PNXmlEPTB;MU[uOFIxQSEQvF2=	MnHHV2FPT0WU
BEN	NH3yRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33Wb2lEPTB;MU[uOVE2PSEQvF2=	M{HPT3NCVkeHUh?=
LB373-MEL-D	M4nVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTQNW1EUUN3ME2xOk44OjN{IN88US=>	M2rXcXNCVkeHUh?=
MEL-HO	MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGruOmdKSzVyPUG2Mlg5PTRizszN	M33Vd3NCVkeHUh?=
GI-ME-N	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmCwTWM2OD1zNj65NFMzKM7:TR?=	NX3RTHh4W0GQR1XS
RKO	NGLRUmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTF5LkC3OFgh\|ryP	NVPGWodnW0GQR1XS
MZ2-MEL	NY[5S2pyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1r4bmlEPTB;MUeuNVM{KM7:TR?=	MlXvV2FPT0WU
NCI-H1573	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHFT\|lKSzVyPUG3MlI5OjZizszN	MkLOV2FPT0WU
NCI-H1581	NGrUeHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLFU\|hKSzVyPUG3MlQ1OTFizszN	NWLmRlJjW0GQR1XS
NCI-H747	NHG3eI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTPTWM2OD1zNz61Nlk4KM7:TR?=	M3TZW3NCVkeHUh?=
SW1783	M1nmWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\iO2lEPTB;MUeuOlQyPSEQvF2=	NULVOHdDW0GQR1XS
Calu-6	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTF5Lk[3PFIh\|ryP	MXXTRW5ITVJ?
SF268	NWPvTnpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGC0Z21KSzVyPUG3MlY6PjlizszN	MlLDV2FPT0WU
ES8	NVvmWYs6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLuO3hKSzVyPUG3Mlg2QTNizszN	MmfpV2FPT0WU
KM-H2	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7neIhDUUN3ME2xO{46PDFzIN88US=>	MmniV2FPT0WU
D-502MG	NGXZXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTF5Lkm4NFgh\|ryP	M4PJNnNCVkeHUh?=
HLE	M2PhNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2X5OmlEPTB;MUiuN\|E1QCEQvF2=	MlmzV2FPT0WU
SW982	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDYTWM2OD1zOD60NFc2KM7:TR?=	NXnqZYFFW0GQR1XS
MDA-MB-361	MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTF6LkW1PFgh\|ryP	NHHzZnVUSU6JRWK=
NCI-H1563	M4Dj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHLZY9KSzVyPUG4MlcyOjRizszN	M1rhdHNCVkeHUh?=
MFE-280	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnteJRKSzVyPUG4MlczQTNizszN	NE\qbHlUSU6JRWK=
U251	M3XncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn2wTWM2OD1zOD63N\|Q4KM7:TR?=	MW\TRW5ITVJ?
KNS-42	MlP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlG1TWM2OD1zOD64NFE2KM7:TR?=	NUfZZlg{W0GQR1XS
U-266	M1zLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2i2NWlEPTB;MUiuPFY1QSEQvF2=	NVjhS41oW0GQR1XS
OVCAR-8	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIf2RZdKSzVyPUG4MlkzPzZizszN	NEPOeJdUSU6JRWK=
MFH-ino	M1jZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXETWM2OD1zOD65OlY6KM7:TR?=	NV\CWmNDW0GQR1XS
D-263MG	MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrZZW11UUN3ME2xPU4xOTd{IN88US=>	NFiyeG5USU6JRWK=
NCI-H1437	MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTF7LkC0Olch\|ryP	M{TkRXNCVkeHUh?=
NCI-H1048	NWHE[3V3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlH0TWM2OD1zOT6yN\|I3KM7:TR?=	MYfTRW5ITVJ?
NCI-H446	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPJWWNKSzVyPUG5MlM2QDlizszN	NUnIbGt2W0GQR1XS
NCI-N87	NU\vToI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfCSlFKSzVyPUG5MlU6QTJizszN	MkTZV2FPT0WU
WM-115	Mn7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTF7Lk[3O\|Qh\|ryP	M{jZPHNCVkeHUh?=
HuH-7	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrFbohHUUN3ME2xPU44PDJzIN88US=>	MWfTRW5ITVJ?
NCI-H650	MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHq0SZRKSzVyPUG5Mlc2ODhizszN	NHq0eIVUSU6JRWK=
TYK-nu	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGD2dmZKSzVyPUG5Mlg{PzhizszN	NWHxPZlRW0GQR1XS
Becker	MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3H5dGlEPTB;MUmuPFU1PyEQvF2=	M33Vd3NCVkeHUh?=
BB49-HNC	MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDNTWM2OD1zOT65NkDPxE1?	M1nOUHNCVkeHUh?=
HGC-27	Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrFd\|JYUUN3ME2yNE4yOzl2IN88US=>	M1vkfXNCVkeHUh?=
SiHa	M{fK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zvdmlEPTB;MkCuN\|cyOiEQvF2=	M2jicXNCVkeHUh?=
LB2518-MEL	M4XINWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHOyZXdKSzVyPUKwMlM4OzlizszN	NWC4VGI3W0GQR1XS
TE-5	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTJyLke0PFIh\|ryP	MVHTRW5ITVJ?
IST-SL1	NWTyO5RmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2OwWGlEPTB;MkCuO\|g4QSEQvF2=	NUDnW4FLW0GQR1XS
A375	MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTJzLkC1Olch\|ryP	NIS5cXZUSU6JRWK=
MC116	MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDvcmNxUUN3ME2yNU4xPzJ\|IN88US=>	NYLnT29pW0GQR1XS
GI-1	NWT3OoQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4X0T2lEPTB;MkGuNVch\|ryP	MVHTRW5ITVJ?
HOP-62	MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml:2TWM2OD1{MT6yO\|g1KM7:TR?=	NYqydZdmW0GQR1XS
PA-1	NE\pcpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLaTWM2OD1{MT6yO\|g4KM7:TR?=	M2PJeXNCVkeHUh?=
HT	NF76VHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2npXmlEPTB;MkGuOFM{OSEQvF2=	NWLpOGx[W0GQR1XS
HUTU-80	NXvV[HpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvPXoFKSzVyPUKxMlQ{OzZizszN	MYjTRW5ITVJ?
NCI-H1975	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTJzLkS2NUDPxE1?	M1PmXHNCVkeHUh?=
GAK	NVfWV4wyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPFTWM2OD1{MT60PVkh\|ryP	M1vBZXNCVkeHUh?=
SK-N-AS	NXfmUoE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\uSmFKSzVyPUKxMlU3OTlizszN	NYrtTmtUW0GQR1XS
OE33	Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jCWGlEPTB;MkGuOlA1PiEQvF2=	MmWzV2FPT0WU
YKG-1	M4T0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTJzLk[1OFUh\|ryP	NWrQfIJsW0GQR1XS
CAL-85	NVTxW49nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfLdIY1UUN3ME2yNU46OzB3IN88US=>	MXHTRW5ITVJ?
NCI-H2347	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPsVlFMUUN3ME2yNU46PDJ6IN88US=>	MoHmV2FPT0WU
PANC-08-13	MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTJ{LkCxNVkh\|ryP	M3HNXXNCVkeHUh?=
SK-N-FI	MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTJ{LkOwO\|Qh\|ryP	M{fMb3NCVkeHUh?=
NEC8	NEjoN3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH:5[nJKSzVyPUKyMlUxPzhizszN	NIrTPIpUSU6JRWK=
AN3-CA	NIXLdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTNS\|dPUUN3ME2yNk43ODh2IN88US=>	NFnkWWxUSU6JRWK=
HuO9	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fNRWlEPTB;MkKuO\|M6PiEQvF2=	MoPCV2FPT0WU
COLO-800	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTJ{Lke2OVMh\|ryP	NHzKZ\|dUSU6JRWK=
HT-29	NFXnN3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFK2UJZKSzVyPUKyMlg5OjNizszN	M17FW3NCVkeHUh?=
OC-314	NGr5e3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYflcpduUUN3ME2yNk45QDR3IN88US=>	MkDyV2FPT0WU
G-401	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTJ\|LkC0OlIh\|ryP	M2DXV3NCVkeHUh?=
Saos-2	M4r1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHmybYlKSzVyPUKzMlUyQDJizszN	NXO5[ZNWW0GQR1XS
UACC-62	Ml:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPLSndXUUN3ME2yN{42QDN\|IN88US=>	MX3TRW5ITVJ?
D-247MG	MkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTQV2xrUUN3ME2yN{44QTN7IN88US=>	MULTRW5ITVJ?
COLO-741	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTJ\|Lkm1OlUh\|ryP	MYrTRW5ITVJ?
ES3	NVLDclRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\C[5pvUUN3ME2yOE4xODJ\|IN88US=>	M3mxOXNCVkeHUh?=
LNCaP-Clone-FGC	NXXJbI1NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7hUllKSzVyPUK0MlAzOTFizszN	Mmi5V2FPT0WU
SW1710	M1TKV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\tTWM2OD1{ND6xOVA3KM7:TR?=	M3q4eXNCVkeHUh?=
LU-99A	M1LnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXVRpIxUUN3ME2yOE4yQDRzIN88US=>	Mo\RV2FPT0WU
HOP-92	NVzKOGdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXpVoFMUUN3ME2yOE44OjVizszN	NWTIdGJlW0GQR1XS
LS-123	NWjYNG9DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFm5cYFKSzVyPUK0Mlk3OTRizszN	NF3wOGNUSU6JRWK=
T84	NHzVOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnCTWM2OD1{ND65O\|Y2KM7:TR?=	MXnTRW5ITVJ?
HCT-116	M{nBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3YTWM2OD1{NT60NVg3KM7:TR?=	NIDDW5JUSU6JRWK=
M14	NUPDVoY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3Oe2ZKSzVyPUK1MlQ1PDdizszN	MVPTRW5ITVJ?
OCUB-M	NIezdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjEWGdKSzVyPUK1MlQ1PTZizszN	NYDQZVR3W0GQR1XS
MKN45	NHPFVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLSTWM2OD1{NT62N\|E2KM7:TR?=	M1SzVHNCVkeHUh?=
LCLC-97TM1	NVPjfo4xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEiwRmZKSzVyPUK1MlczQDVizszN	MUTTRW5ITVJ?
RVH-421	MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPm[WhKSzVyPUK1MlgyPjFizszN	NYPJS2tPW0GQR1XS
NKS-81-FD	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XWb2lEPTB;MkWuPVAzOSEQvF2=	MW\TRW5ITVJ?
NCI-H596	M3vzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXzU4xYUUN3ME2yOk4xPDh5IN88US=>	NH\6fm9USU6JRWK=
GB-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTCTWM2OD1{Nj6xPFc6KM7:TR?=	NVTacIhkW0GQR1XS
ZR-75-30	MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILmWY5KSzVyPUK2MlIzQTdizszN	M1X3WnNCVkeHUh?=
U-2-OS	NV7heVNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLYfHhKSzVyPUK2MlM4PTdizszN	M1e5eHNCVkeHUh?=
HuP-T3	M2XBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M133RmlEPTB;Mk[uOlExOiEQvF2=	MnPhV2FPT0WU
MOLT-16	NYTxd4h4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVO4V3dCUUN3ME2yOk43OTZ4IN88US=>	MYrTRW5ITVJ?
U-87-MG	NGO3dHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PqSmlEPTB;Mk[uO\|Q{QCEQvF2=	NXfNNXo5W0GQR1XS
8505C	NXjQenB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mof4TWM2OD1{Nj65NVI3KM7:TR?=	NUjUfGZvW0GQR1XS
SK-MEL-3	NX;Bd5B[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTJ4Lkm4Nlgh\|ryP	MUPTRW5ITVJ?
COLO-824	NGDvN2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPyTWM2OD1{Nz6yNVk2KM7:TR?=	MWPTRW5ITVJ?
EW-1	MnrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzLfGhIUUN3ME2yO{4{PTV2IN88US=>	MoXCV2FPT0WU
UACC-257	M13yNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHn2VVNKSzVyPUK3MlM5ODRizszN	MXjTRW5ITVJ?
Hs-578-T	NFL5NIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTJ5LkWyPVkh\|ryP	MkjSV2FPT0WU
UACC-893	MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfXNnlKSzVyPUK3MlY3OzFizszN	MoPCV2FPT0WU
MHH-NB-11	NE\We4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{O2fGlEPTB;MkeuPFAxPyEQvF2=	NGfyUGRUSU6JRWK=
KYSE-410	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTBbJZxUUN3ME2yPE4zPzd7IN88US=>	MkXhV2FPT0WU
SF126	MkjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nLNWlEPTB;MkiuO\|Q{PSEQvF2=	NFr3NYhUSU6JRWK=
HT-144	NHOyVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTJ7LkOzOlIh\|ryP	NEXRXXlUSU6JRWK=
SW1573	NGHvSFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmO4TWM2OD1{OT6zOVA6KM7:TR?=	NVLBVJY6W0GQR1XS
SW620	NIH6Rm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXNe\|ZIUUN3ME2yPU4{PjRzIN88US=>	MYjTRW5ITVJ?
SCH	M4P1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTJ7Lki4N\|Eh\|ryP	M1LlfHNCVkeHUh?=
EW-22	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkD0TWM2OD1\|MD6xPVY6KM7:TR?=	NYPreGxJW0GQR1XS
H4	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjSTWM2OD1\|MD60OlU1KM7:TR?=	MmLoV2FPT0WU
CAS-1	NFTBZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTNyLke4OVkh\|ryP	M3vEbnNCVkeHUh?=
MG-63	MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTNyLki0O\|gh\|ryP	M{\VTHNCVkeHUh?=
MDA-MB-415	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIr3T3BKSzVyPUOxMlE4PTNizszN	MXfTRW5ITVJ?
NCI-H1395	NFGzVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1:xdGlEPTB;M{GuNlMzQCEQvF2=	NEntOppUSU6JRWK=
Ca-Ski	MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TBb2lEPTB;M{GuN\|E4PyEQvF2=	MlHDV2FPT0WU
BxPC-3	NXXVflVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkOzTWM2OD1\|MT6zO\|I6KM7:TR?=	MU\TRW5ITVJ?
A3-KAW	NGH1WG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\tRWlEPTB;M{GuOFQ4OSEQvF2=	NUjUcWJIW0GQR1XS
T-24	NGH3VVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn2wTWM2OD1\|MT63N\|YzKM7:TR?=	MULTRW5ITVJ?
NCI-H2029	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\hTGlEPTB;M{GuO\|c3PSEQvF2=	MVnTRW5ITVJ?
YAPC	M1:5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHqeFlKSzVyPUOyMlA1ODdizszN	MWrTRW5ITVJ?
SK-MEL-2	M{Lobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1m3SmlEPTB;M{KuNFUzKM7:TR?=	NXPhXZd{W0GQR1XS
LS-513	M1ztb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnUOGZKSzVyPUOyMlEyQDdizszN	MWPTRW5ITVJ?
AsPC-1	NHfi[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTN{LkO2NFUh\|ryP	NFv1WJVUSU6JRWK=
KYSE-150	NXfEVHZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzvOmpOUUN3ME2zNk4{Pzd\|IN88US=>	M4WxbnNCVkeHUh?=
NCI-H520	NIP1bFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\yelZKSzVyPUOyMlQ1QDJizszN	MlLxV2FPT0WU
JEG-3	M2PXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfMTWM2OD1\|Mz6wPVcyKM7:TR?=	NYe0dlhMW0GQR1XS
GMS-10	NVjlPW1pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTN\|LkOwNFQh\|ryP	M1;LXnNCVkeHUh?=
HT-1080	NXv5[ZQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTN\|LkO5JO69VQ>?	MX;TRW5ITVJ?
NCI-H1651	NY[3Z3lnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEm5T5pKSzVyPUOzMlM6PiEQvF2=	MWfTRW5ITVJ?
NCI-H2122	M4[2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTN\|LkW1O\|Qh\|ryP	MWfTRW5ITVJ?
ES5	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\hZlZKSzVyPUOzMlczQTJizszN	NHnvVWRUSU6JRWK=
8305C	NXe5RZduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zxbmlEPTB;M{OuPVk{PyEQvF2=	M{nsSXNCVkeHUh?=
KM12	NYPJTZBoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPybG9KSzVyPUO0MlA1PzhizszN	NUnsRpNNW0GQR1XS
HCT-15	NVOz[WtHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXzfWhnUUN3ME2zOE4yOjdizszN	MnzEV2FPT0WU
OVCAR-5	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEn3c5lKSzVyPUO0MlIyQDJizszN	MXvTRW5ITVJ?
NCI-H2291	M4m5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7JUphEUUN3ME2zOE4zPDd{IN88US=>	MUPTRW5ITVJ?
CP50-MEL-B	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{S5RWlEPTB;M{SuOlU6OiEQvF2=	MkHSV2FPT0WU
C-33-A	NUXPeZFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTN2Lk[4OVch\|ryP	MoDHV2FPT0WU
NCI-H2452	NVG3RZRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYG0Olg4UUN3ME2zOE44QDh{IN88US=>	MYPTRW5ITVJ?
MDA-MB-157	NH33S4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnH1TWM2OD1\|ND64NVk{KM7:TR?=	NWLWeo5FW0GQR1XS
LN-405	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnjO2tKSzVyPUO1MlQ{ODhizszN	NUewNHc5W0GQR1XS
MDA-MB-231	NVjFdHBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPjU4ZKSzVyPUO1MlUxPTRizszN	NF2wOY5USU6JRWK=
EW-24	NXnWdVFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXWxb4Z{UUN3ME2zOU43OzN3IN88US=>	NUXBWZpGW0GQR1XS
MKN28	MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljkTWM2OD1\|NT64NlM3KM7:TR?=	M13TRXNCVkeHUh?=
KINGS-1	M37pVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTN3Lki0N\|Qh\|ryP	MlTDV2FPT0WU
LC-2-ad	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPM[oQ{UUN3ME2zOk43QTlizszN	NHjmTGxUSU6JRWK=
IGR-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTN4LkewO\|Uh\|ryP	NYflZ2YxW0GQR1XS
SW626	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnnWYR5UUN3ME2zO{4xPDF5IN88US=>	NXi3NllSW0GQR1XS
ONS-76	NF\iT2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\DS2lEPTB;M{euNVMxQSEQvF2=	NHXLS5hUSU6JRWK=
T98G	NWLMfW8yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\6TWM2OD1\|Nz64OlM2KM7:TR?=	NWjHPVJ[W0GQR1XS
NB14	MlPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fFemlEPTB;M{iuOFU1PCEQvF2=	NF3le5hUSU6JRWK=
D-423MG	NHT0PVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTwVZhKSzVyPUO4MlQ5PjlizszN	MkfQV2FPT0WU
NCI-H510A	MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDZbHFKSzVyPUO4MlY1PTFizszN	MkjsV2FPT0WU
NMC-G1	NFPNZ3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfwTWM2OD1\|OD63NlIzKM7:TR?=	NEKycW9USU6JRWK=
SW948	M4LheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\PPHhKSzVyPUO4Mlg6PDlizszN	NWL4WYFMW0GQR1XS
MFM-223	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfmUXlKSzVyPUO4Mlk1OzFizszN	NXHud3p1W0GQR1XS
PAN1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TnPWlEPTB;M{iuPVkyQSEQvF2=	MlrOV2FPT0WU
MZ7-mel	NXvzdYt[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TDWWlEPTB;M{muNVE6QSEQvF2=	NH\iV\|VUSU6JRWK=
COLO-679	NHrY[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HZU2lEPTB;M{muPVcxQCEQvF2=	NFHoPGhUSU6JRWK=
SW872	M{XVW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzwN5VlUUN3ME20NE4zODNzIN88US=>	MkS4V2FPT0WU
HT-1197	MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTRyLkK4Olkh\|ryP	M1;tOnNCVkeHUh?=
ES6	NEDDTpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTRyLkS1OVIh\|ryP	NIDGSYxUSU6JRWK=
SNU-387	NHTEV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4XkSWlEPTB;NECuPFI{QCEQvF2=	NHG4RVBUSU6JRWK=
T47D	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\3d25KSzVyPUSxMlAyQTJizszN	M3zEXHNCVkeHUh?=
G-402	M{fCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILLcIJKSzVyPUSxMlA5ODlizszN	NEjqZ5RUSU6JRWK=
MZ1-PC	NYjFfGh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGP2VXBKSzVyPUSxMlgyKM7:TR?=	NYmxfGFVW0GQR1XS
SW1417	Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjOdHhnUUN3ME20Nk4{ODNizszN	MXLTRW5ITVJ?
RERF-LC-MS	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnH[5BXUUN3ME20Nk42ODh5IN88US=>	NFO4WnRUSU6JRWK=
SF539	NUTS[GtRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\6TWM2OD12Mj61OVI6KM7:TR?=	MlH2V2FPT0WU
ESS-1	MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnT3TWM2OD12Mz61OVU5KM7:TR?=	NGrqSohUSU6JRWK=
RO82-W-1	NXHtW2R3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWf0dWI4UUN3ME20N{43OTV\|IN88US=>	MnTvV2FPT0WU
S-117	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIK0XFBKSzVyPUSzMlY6PThizszN	MWnTRW5ITVJ?
SW756	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDKZ\|FKSzVyPUSzMlgzPDJizszN	M3O4[3NCVkeHUh?=
CP66-MEL	M4njfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGf0VopKSzVyPUS1MlcyPDNizszN	MmPzV2FPT0WU
H-EMC-SS	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\xO2ZKSzVyPUS1Mlc3QTNizszN	NYDWXGxMW0GQR1XS
NCI-H2052	NViyPHBLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjIXXBCUUN3ME20OU46ODJ5IN88US=>	NYHid4lLW0GQR1XS
SW684	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlS0TWM2OD12Nz6wNFgyKM7:TR?=	NYPISJU4W0GQR1XS
HCC1569	NYjBfZd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\4fWlEPTB;NEeuNVY2QCEQvF2=	M{LtXnNCVkeHUh?=
KGN	NU\odXJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\CZmRKSzVyPUS3MlM{OTFizszN	NV[5W2lIW0GQR1XS
LCLC-103H	MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfMTZdzUUN3ME20O{41PDB2IN88US=>	NVPqTHFGW0GQR1XS
SW780	M3W2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHKTWM2OD12Nz62N\|UyKM7:TR?=	Ml3VV2FPT0WU
NCI-H1703	NV7VPZZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTR6LkOzOVIh\|ryP	MnrjV2FPT0WU
HCC1395	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\wVXJvUUN3ME20PE44PDN{IN88US=>	MnXXV2FPT0WU

... Click to View More Cell Line Experimental Data

体内研究

Gefitinib 作用于无胸腺裸鼠，抑制SKOV3 或MDA-MB-231 肿瘤生长。Gefitinib高效作用于两种类型肿瘤。处理14天后，MDA-MB-231肿瘤和SKOV3肿瘤生长抑制分别为71%和32%。

细胞实验：^[1]	+ 展开 Cell lines: NR6, NR6M 和 NR6W 细胞 Concentrations: 0 μM -2 μM Incubation Time: 72 小时 Method: 呈指数生长的细胞，包括 NR6, NR6M, NR6M和NR6W细胞按6倍接种在96孔板上，每孔为2000个细胞, 粘附，随后在PBS 中清洗，然后在含0.5% FCS的培养基上温育过夜。使用不同浓度(0-2 μM) Gefitinib或溶质对照DMSO 和EGF 处理细胞。诱导NR6wtEGFR和NR6W 细胞增殖的EGF最佳浓度已经测定，因此NR6wtEGFR和 NR6W 细胞中分别加入10 nM和 0.1 nM EGF。NR6 和NR6M细胞中不加入EGF。72 小时后，通过MTT 增殖检测测量细胞数。 (Only for Reference)
动物实验：^[3]	+ 展开 Animal Models: 携带 SKOV3或MDA-MB-231肿瘤的无胸腺裸鼠 Formulation: 0.2% DMSO Dosages: 75 mg/kg Administration: 饲喂处理 (Only for Reference)

参考文献

+ 展开

溶解度 (25°C)

体外	DMSO	89 mg/mL (199.14 mM)
	Ethanol	4 mg/mL (8.95 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 1% CMC Na	30mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Gefitinib (ZD1839) SDF

分子量	446.90
化学式	C₂₂H₂₄ClFN₄O₃
CAS号	184475-35-2
稳定性	3 years -20°C powder
稳定性	2 years -80°C in solvent
别名	N/A

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2018-11-15)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00025675	Completed	Brain and Central Nervous System Tumors	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI)	October 9 2001	Phase 2
NCT03050164	Completed	Bioequivalence Study	Hunan Kelun Pharmaceutical Co. Ltd.	September 8 2016	Phase 1
NCT00684385	Completed	Non Small Cell Lung Cancer\|Cancer of the Head and Neck	AstraZeneca	August 8 2001	Phase 4
NCT01933347	Active not recruiting	Non Small Cell Lung Cancer	Guangdong Association of Clinical Trials	April 7 2014	Phase 2
NCT02411448	Active not recruiting	Metastatic Non-Small Cell Lung Cancer	Eli Lilly and Company	May 6 2015	Phase 3
NCT03486496	Not yet recruiting	Lung Adenocarcinoma\|EGFR Mutation	Fujian Cancer Hospital	June 5 2018	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
I try to dissolve Gefitinib (ZD1839) in 0.5% methylcellulose+0.2% Tween 80 for in vivo experiments. However, when I prepare the mixture, it forms precipitates. Exists another way to dissolve completely the compound?
回答：
S1025 can be dissovled in both 5% DMSO+corn oil and 5% DMSO+30% PEG 300+5% Tween 80+ddH2O at 2.5 mg/ml clearly. It dissolves in DMSO not readily, please sonicate and warm it in water bath at about 45 degree, and dissolve it clearly first. Then add other solvent.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

泛EGFR抑制剂

AZD8931 (Sapitinib) : Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.
活性最高的EGFR抑制剂

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA批准的EGFR抑制剂

Lapatinib : Approved by FDA for breast cancer.
最新的EGFR抑制剂

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

研究领域

产品类型

Gefitinib (ZD1839)

客户购买Selleck的此次产品后发表的文献93篇：

客户使用该产品的14个实验数据：

产品安全说明书

EGFR抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Gefitinib (ZD1839) SDF

计算器

摩尔浓度计算器

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2018-11-15)

技术支持

常见问题及建议解决方法

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

相关EGFR产品